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INTRODUCTION 
          Siddha is one of the oldest systems of medicine originating in ancient 
Tamilakam (Tamil Nadu) in South India and Sri Lanka.  The Siddha system of 
medicine deals with physical, psychological, social and spiritual well-being of an 
individual. Diet and lifestyle play a major role not only in maintaining health but 
also in curing diseases.  
 
              Siddha system believed to be originated from AGATHIYAR to Siddhars, 
from Siddhars this system of medicine gifted to mankind. The ultimate aim of 
Siddhars is to attain external bliss. For attaining external bliss, human body is 
considered to be a media. They held that the body is the only instrument with 
which one could attain success in spiritual evolution and thereby get rid of 
diseases, decay & death.  
           
            “IRAI MAATRU IRUAI”. IRAI means food, food is the basic material 
which the body need for it survival for healthy life one should consume a healthy 
food. If there is any altered in health the same food can be given in other form (i.e 
MAATRU IRAI) like kudineer, chooranam, etc, 
 
             The advantage and unique features of Siddha systems is the removal of the 
root cause of the disease and provide perfect remedy for mind and soul. 
 
            The monumental Tamil composition “Thirukkural” gives a synoptic 
account of the base of medical theory and practice in ten extremely condensed two-
line verses. 
           
“Diagnose the illness, seek out its cause, 
Study the way of cure and treat it right”. (948)  
 
“Patient’s condition, severity of illness and duration known for sure 
Let the physician versed in his lore prescribed the remedy”. (949) 
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“Patient, physician, medicine and nurse 
Are the four bearing on the art of healing”. (950) 
 
                 
 This chapter on medicine apart, Thirukkural on the whole has the words noy 
and pini (disease) referred to in as many as 50 places. Beside, cause of diseases, 
mental illness, allergy, environmental pollution, burns, scar, wounds, ulcer, 
pustules, etc., have contexts of occurrence in this work, along with an implicit 
emphasis on healthy mind in healthy body. 
           
                   In Siddha system of medicine, the disease “SAGANA VADHAM” are 
brought under the types of vadha diseases. And it is correlated with “Cervical 
spondylosis”. Cervical spondylosis is defined as “ARTHROSIS” Of the posterior 
intervertebral joints in the cervical   vertebrae.  
 
                    In India, More than 10 millions of cases per year are affected by 
cervical spondylosis. The prevalence of cervical spondylosis is similar for both 
sex. The incidence of neck pain in adult is approximately 20-50% per year. 60% of 
the population older than 45 years of age and 80% older than 65 years of age 
account for the case of cervical spondylosis reported.  
                  The pain management is the upcoming strategic in this era. Treatment 
for cervical spondylosis is steroids and NSAIDS. There is no satisfactory and 
permanent cure for cervical spondylosis in allopathic system of medicine. So the 
world is looking forward for an alternative treatment. The need  is development of 
effective and safe analgesic drug in traditional way. 
           So the need  of the hour is to search an effective drug and therapy to treat 
cervical spondylosis with less or no adverse effects. So i have ventured to compare 
the efficacy of poly herbal  drug “POORANATHI CHOORANAM” (Internal) and 
“VALI KUTHALUKU ULLI ENNAI” (External)  with supporting   therapy 
“OTTRADAM” for the management of saganavatham (cervical spondylosis).  
AIM & OBJECTIVES  
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AIM & OBJECTIVES 
 
AIM:  
To evaluate the therapeutic efficacy of siddha trail drugs “ Pooranathi 
Chooranam ”(internal), “ValiKuthaluku Ulli Ennai” (External) and with supporting 
therapy “Ottradam” on saganavatham (Cerviacl spondylosis)  
 
OBJECTIVES:  
PRIMARY OBJECTIVE:  
To evaluate the therapeutic efficacy of siddha trail drugs “ Pooranathi Chooranam” 
(internal), “Vali Kuthaluku Ulli Ennai” (External) and with supporting therapy 
“Ottradam” on saganavatham (Cervical spondylosis) 
 
SECONDARY OBJECTIVE:  
 To standardize the standard operating procedure for both siddha trail drugs. 
Standardization through both traditional modern analytical techniques  
 Evaluation of acute and sub- acute toxicity studies for the trail drug “Pooranathi 
Chooranam” 
 To evaluate the pharmacological activity Anti-inflammatory and analgesic 
activity of the trail drug “Pooranathi Chooranam” in animal model  
 To evaluate the safety of the trail drug Pooranathi Chooranamin saganavatham 
patients before and after treatment  
 To have clinical trial drugs “Pooranathi Chooranam” (int) and “Vali Kuthaluku 
Ulli Ennai” (ext) in the treatment of “saganavatham”  
 To demonstrate the methodology of Ottradam therapy in treating of 
Saganavatham 
 To create a knowledge about the siddha medicine and prove the efficacy of siddha 
drug for the disease of Saganavatham (Cervical spondylosis) 
REVIEW OF LITERATURES – SIDDHA ASPECT  
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3.REVIEW OF LITERATURES 
 
3.1 SIDDHA LITERATURE REVIEW: 
 
Siddha system surmise that the human body is composed of  96 thathuvam and 
72000 blood vessles and nerves beyond these, there are 10 naadi, 10 vaayu, and 
14vegangal. All of them play vital roles in various functions of the body. That 10 
Naadifurther divided into 3 humors i.e Vatham, Pitham, Kabam and these are also called 
as Uyir Thathu, which is most important for the formation and maintenance of the body, 
if any disturbance in their equilibrium leads to ill health. 
 
Based on vatha, pitha, kapha theory.Vatha diseases get a major role among that. 
The literature of  “Yugi Vaidhiya Chinthamani 800”, classified the vatha disease  into 84 
types. Saganavatham is one of the vathadisease. Before reviewing the specific signs and 
symptoms of saganavatham, the details of vatham is described under the following 
headings. 
 
VATHAM: 
 
 Vaatham is formed by Aahaayam and Vaayu, controls the nervous action 
thatconstitute movement, activity, sensation, etc. 
 Vatham predominates in the bone. 
 It isresponsible for the production implementation of thoughts to action.  
 Generally, itsfunction is more related to cerebral activities like, thinking and 
action. 
 Vatham predominates in first one third of life when activity, growth, sharpness of 
function of sense, is greater.  
 However Vadham represents Vayu, Mind, Dryness, Pain, Flatulence, Sensitive, 
Lightness 
LOCATIONS OF VATHAM: 
Seats of vatham : Below the naval 
Generally, vatham lives in 
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1. Abanan 
2. Edakalai  
3. Kaamakodi 
4. Undhiyinkeezhmoolam 
5. Muscles 
6. Bones 
7. Hair follicles 
8. Nerves 
9. Skin 
10. Joints 
11. Stools 
Physiologically, vatham which has no alteration lives GI track, bones, ear, thigh, 
hip and skin. 
NATURAL PROPERTIES OF VATHAM: 
1. Giving briskness 
2. Expiration and inspiration 
3. Functioning the seven udalkattugal, uniformly 
4. Functioning the mind, thoughts and body 
5. Regulation of 14 physiological reflexes 
6. Protection and strengthening of the five sensory organs. 
IMBALANCE OF VATHAM: 
1. Body ache 
2. Tearing pain 
3. Pricking pain 
4. Nerve weakness 
5. Dryness 
6. Movements 
7. Shivering 
8. Mental distress 
9. Weakness 
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10. Traumatic pain 
11. Joint pain 
12. Dislocation of joints of upper & lower limbs 
13. Weakness of organs 
14. Pilo-erection 
15. Paralysis of the limbs 
16. Polydipsia 
17. Bony pricking pain 
18. Severe pain in calf and thigh muscles 
19. Anuria and constipation 
20. Unable to do flexion and extension of limbs 
21. All tastes to be like astringent 
22. Astringent salivation 
23. Darkness of skin, eye and urine. 
QUALITIES OF VATHAM: 
OWN QUALITIES: 
1. Kadinam – hardness 
2. Varatchi – dryness 
3. Elesu – lightness 
4. Kulirchi – coolness 
5. Asaidhal – mobility 
6. Anuthuvam – subtleness 
OPPOSITE QUALITIES: 
1. Miruthu – soft 
2. Parumai – unctuous 
3. Paluvu – heavy 
4. Akkini – hot 
5. Sthiram – stable 
6. Katti– solid 
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RELATION WITH FIVE ELEMENTS & SIX TASTES: 
  Vatham –Vaayu + Aahaayam 
If vaayu and aahaayam or any of them is decreased or increased from the normal 
level, it will surely lead to pathological state of vatham. 
Regarding diet, bitter, pungent and astringent tastes contain vali (vaayu) and bitter 
alone contains aahaayam. So if these are consumed in large amounts this results in the 
vitiation of vatham and eventually vatha diseases. 
DESCRIPTION OF VATHAM: 
The siddha classical texts divide the general principles of vatham into ten 
subsidiary forms that differ from one another by their localization in the body and by 
their particular functions. They are, 
1. PRANAN (Uyirkaal): 
It corresponds to the cardiac plexus and refers to the chest. It regulates the 
respiratory system and helps the digestive system. It’s derangement causes respiratory 
disorders. 
2. ABANAN (Kizhnokkumkaal): 
It corresponds to the pelvic plexus and expels fecal matter and urine. It constrict 
the anal sphincter. It helps to spread the digestive food all over the body. It is also 
responsible for the expulsion of sperm and menstrual flow. Its derangement leads to 
diseases of the bladder, rectum and reproductive system. 
3. VIYANAN (Paravukaal): 
It corresponds to the vaso-ciliary at the root of the nose and base of the skull and 
contents will. Vyanan spreads over the body in all endings and causes constriction and 
relaxation of  both voluntary and involuntary muscles. This is responsible for the 
movements of the body and sensory perceptions. 
REVIEW OF LITERATURES – SIDDHA ASPECT  
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It causes flow of fluids, flow of sweat, opening and closing of eyes etc., it is 
responsible for taking the absorbed essence of the food to the different parts of the body. 
The neurological problems of the body are basically because of the derangement of 
vyanan. 
4. UDHANAN (Melnokkumkaal): 
It corresponds to the pharyngeal in the throat region and regulates the higher 
functions of brain like speech. Its derangement causes symptoms of upper gastro 
intestinal tract diseases, problems in speech etc. it is also responsible for the 
physiological reflex actions like vomiting, hiccup, cough, sneezing etc. 
5. SAMANAN (Nadukkal): 
It corresponds to the solar plexus in the naval region and controls digestion. It act 
as a neutralizing air for the upward and downward air (abana & udhana). Its derangement 
will cause gastrointestinal symptoms and neurological, repiratory  symptoms as this vayu 
is the neutralizing force for the other four vayus. 
6. NAGAN: 
Nagan is responsible for the intelligence of an individual. It causes opening and 
closing of eyelids. Its derangement causes impaired memory and lack of coherent. 
7. KOORMAN: 
This causes yawning and closure of eyelids. This is responsible for vision lacrimal 
secretion is also attributed to koorman. It gives energy to the body and helps in body 
building. 
8. KIRUGARAN: 
This lies in the tongue, salivary glands, nasal secretion, hunger, concentration of 
the mind on one particular thing, sneezing, cough are all attributed to kirugaran 
 
REVIEW OF LITERATURES – SIDDHA ASPECT  
9 
 
9. DEVADHATHAN: 
Laziness is attributed to this vayu. The ocular movements, human passions like 
anger are attributed to this vayu. 
10. THANANJEYAN: 
It produces swelling all over the body and leaves from the body by blowing of the 
cranium only on the third day after death. This vayu is responsible for decay of the body 
after death. 
VATHA NOI  
DEFINITION: (IYAL) 
Vatha is the principle of motion in the body and mind. When Vatham is healthy, 
the movement of the body are graceful, unimpeded and yet controlled. When out of 
balance the movements become erratic, excessive, decreased, or blocked and manifest the 
clinical symptoms of pricking pain, stabbing pain, and severe pain and atlost, paralysis 
may occur Symptoms manifested due to raise of Vatham and cause Vatha disease. In 
vatha diseases, the one and more symptoms can be seen. 
1. Having Astringest taste in the mouth 
2. Thirst 
3. Dryness 
4. Constipation 
5. Blackish discoloration of skin, eyes and faces 
6. Numbness 
7. Pain 
8. Rigidity 
9. Lack of movements 
10. Internal bone pain 
11. Inflammation of joints 
12. Paralysis of limbs 
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AETIOLOGY OF VADHA DISEASES: 
According to yugi vaithya cindhamani 
“                      
                              
                           
                               
                          
                              
                         
                       ” 
 
“                         
                        
                      
                     
                      
                      
                            
                                                                     ”.  
 
• Excessive sexual indulgence 
• Over consumption of bitters, astringents and rancid foods. 
• Drinking rainwater 
• Day time sleep 
• Night timework 
• Starvation 
• Lifting overweight 
• Will initiate and aggravate vali 
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As per KonganavarVadhaKaviyam 
 
“                              
                           
                            
                         
                          
                         
                          
                       ” 
 
           : 
 
“                                     
                                  
                                  ” 
 
• Excessive exposure to the sun 
• Excessive intake of water 
• Postponed of proper intake of food 
• Excessive intake of bitter gourd 
 
According to AgathiyarKanmaKaandam 
“                         
                                  
                       
                     
                     
                                           
                                 ” 
 
• cutting trees and barks 
• Breaking the legs of living animals 
• cutting the leaves of living trees 
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According to Agathiyar Gunavagadam, 
“                          
                          
                         
                      
                       ” 
 
• Muscular diseases 
• Menorrhagia 
• Consumption of improper preparation of metallic compounds like mercury and 
lead will cause vadha diseases 
 
CHARACTERISTIC FEATURES OF VATHA DISEASE: 
1. As per TheraiyarVaagadam: 
“                                  
                                        
                                     
                                         ” 
 
• Loss of appetite 
• Pain and redness 
• Fever and cough 
• Insomnia 
• Shivering 
• Hyperpyrexia 
   “                                        
                                           
                                        
                                    ” 
 
• Chillness of the body 
• Rigor and spasm 
• Pain and tenderness of joints 
• Swelling of thejoints. 
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In AaviyalikkumAmuthamuraiSurukkam 
“                       
                          
                       
                             
                           
                          
                              
                    ” 
 
• Fatigue, tiredness 
• Nausea 
• Loss of appetite 
• Pricking sensation all over the body 
• Pain all over the joints. 
• Diarrhoea 
• Azoospermia 
• Incontinence of urine 
• Difficulty in flexion and extension 
• Constipation 
Agathiyar 2000 
“                                    
                                     
                                       
                               ” 
 
 Giddiness 
 Redness of eyes 
 Stabbing pain in the face 
 Abdominal distension 
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 Joint pain in upper and lower limbs 
 Oliguria 
 Drowsiness 
 Chillness of the body 
              
“                                    
                                  
                                  
                                  ” 
 
 Pain in the joints 
 Headache 
 Excessive  yawning 
 Constipation 
 Burning sensation of the body 
 Paralysis 
 Excessive salivation 
 Chillness and tremor 
 
SAGANA VAADHAM: 
DEFINITION: 
 
A vaadha disease, which is formed due to the compression of cervical spine nerves, 
Which are passing along the two sides of cervical vertebrae and the adjacent 
arteries.“Sganavaadham” is one of the vaadha diseases, which is describe in “ Yoogi 
munivar vaidiya sindhamani perunool-800”, T.V. Sambasivampillai says in his agarathi. 
It is a condition which deals with the involvement of upper back of pain in the neck, 
radiating pain in upper limb, feeling heaviness of body, mental depression, giddiness and 
burning sensation of the eye and constipation. 
 
 
REVIEW OF LITERATURES – SIDDHA ASPECT  
15 
 
கேளூக஫ ேழுத்தி ேீ ழர஭க்கு க஫லுங் 
கேடி஬ான ே஭஫ி஭ண் டு ஫ிேகே க ாந்ண௃ 
ோளூக஫ சரீ஭க஫யாங் ேனத்தி ருக்கும் 
ோயிபர்க்கு ஫னங்ேண்  ஫஬க்ே ஫ாகும் 
ஏளூக஫ ஬ி஭ண்டுேண்ணு   ரிச்ச லுண்டா 
க஫ற்ம஫ாய் சயந்தானு ஫ி ேிக் ோணூந் 
கதளூக஫ கோட்டினண௃ கபாற்ே டுக்கும் 
சேனோ தத்தினிட தரீ்க்ேந் தாகன. 
 
1. Pain in the neck. 
2. Radiating pain to the shoulder and upper limb, 
3. Heaviness of body 
4. Mental depression 
5. Giddiness 
6. Burning sensation of the eyes 
7. Constipation 
8. Tingling sensation and numbness of the upper limb. 
 
 
PINIYARI MURAIMAI (DIAGNOSIS): 
It is very important part of the treatment; it is helpful to select the correct line of 
treatment and good prognosis. It is based upon the following diagnosis methods. 
  
1. PORIAAL ARITHAL: 
The physician should examine the patient’s porigal by his porigal. 
1. Mei   – For Feeling touch sensation 
2. Vaai   –For knowing taste 
3. Kan   – For vision 
4. Mookku  – For knowing the smell 
5. Sevi   – For hearing 
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2. PULANAAL ARIDHAL: 
The physician should examine the patient’s pulangal by his pulangal 
1. Ooru -Touch ( perception of sensation ) 
2. Osai            -Sound ( perception of sound ) 
3. Suvai -Taste ( perception of  taste ) 
4. Oli  -Vision ( Perception of vision ) 
5. Naatram -Smell ( Perception of smell ) 
 
3. VINAADHAL: 
The physician should interrogate about the patients name, age, occupation, native, 
socio-economic status, dietic habits, prone to any allergens, complains, history of 
previous illness, history of present illness, family history, habits and frequency of 
attacks, if the patient is in the stage of unability to speak or a `child, physician 
should interrogate the details with his immediate relatives who are taking care of 
him. 
 
4. ENN VAGAI THERVUGAL: 
The prime method adopted to diagnose the disease is by mean of ennvagai 
thervugal. The value of Ennvagai thervugal is very important for diagnosing purpose, 
which is the unique and special method describing in Siddha system of medicine. Hence 
the diagnosis is made by the following 
1. NAADI (PULSE): 
The study of naadi is the important factor in Envagai thervugal which gives 
almost the correct diagnosis, Naadi may studied at 10 points which are Heel, Genital 
organ, Abdomen, Chest, Ear, Nose, Neck, Hand, Eyebrow and Vertex. But the study of 
naadi at hand is the best because the radial artery is located here superficially. The unique 
factor which pertaining the soul in the body is known Naadi. 
Naadi must be studied in right hand for men and left hand for women. After the 
age of fifty, it is reversible that means left hand for men and right hand for women. This 
may due to senile changes. 
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The three uyirthaadukkal are formed by combination of 
Edakalai + Abanan  =>Vaadham 
Pinkalai+ Piranan   =>Piththam 
Suhummunai + Samanan  =>Kabam 
 
They can be felt one which below wrist on the radial side by means of palpation with tips 
of the index, middle and ring fingers corresponding of vaadham, piththam, kabam 
respectively, The three humours exists in the ratio of 1: ½: ¼ normally, Derangements of 
this ratio leads to various diseases. 
 
Cases of vaadha diseases the following stages of naadi are seen. 
1. Exaggeration of vaadham 
2. Vaadha pitha thondha naadi 
3. Vaadha kaba thondha naadi 
4. Kaba vaadha thondha naadi 
5. Kaba pitha thondha naadi 
 
2. SPARISAM (PALPATION): 
By sparisam, the temperature of skin (hot and cold), smoothness or roughness, sweat, 
dryness, hard patches, swelling, growth, of abdominal organ, tenderness, nourishment can 
be felt. 
 
3.NAA (TOUNGE): 
By the examination of tongue, its colour, coating, dryness, deviation, movements, 
variation in taste and gums can be noted. 
 
4. NIRAM (COLOUR): 
By the examination of niram the type of dhegam (Body), cyanosis, redness, pallor and 
yellowish discoloration can be noted. 
 
1. Vaadhadhegi  – Dark colour 
2. Pithadhegi  – Yellow or Red colour 
3. Kabadhegi  – White or Yellow colour 
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5. MOZHI (SPEECH OR VOICE): 
In the examination of mozhi the pitch of voice (low or high) action of slurring and speech 
hallucination can be noted. 
 
6. VIZHI (EYE): 
By the examination of vizhi, pallor, redness, yellowishness, dryness, lacrimation, 
sharpness of vision must be noted. 
 
7. MALAM (STOOLS): 
By the examination of malam, It’s nature, colour, quantity, presence of blood or mucous 
can be noted. 
 
8. MOOTHIRAM (URINE): 
The examination of urine is classified in to two type 
 
a) NEERKURI: 
It includes examination of colour, odour, deposits, quantity and frothy nature. 
b) NEIKURI : 
Preparation of patient: 
Prior to the day of urine examination for neikuri and neerkuri, the patient is 
advised to take the balanced diet and quantity of food must be proportionated into his 
appetite. He should have a good sleep. 
 
METHOD - After waking up in the early morning urine collected in the glass container 
must be examined within 1 ½ hours, a drops of gingili oil is added through the side of 
vitreous without any disturbing. The nature of neikuri should notice in direct sunlight. 
 
OBSERVATION:-  
If the drop of oil, 
1. Lengthens like a snake – vaadhaneer 
2. Spreads like ring – pithaneer 
3. Appears like pearl – kabaneer 
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4. Spreads like snake in ring, ring in pearl, snake in pearl – thondhaneer  
Besides Ennvagaithervugal, a disease can also be diagnosed by means of other methods 
namely thinaigal, paruvakaalangal, uyirthaadhukkal, udalthaadhukkal, gnaanendhiryangal 
and kanmendhiriyangal, hence through a knowledge about the disease can be studied out 
systematically and properly in Siddha system of medicine. 
 
5. UYIR THAATHUKKAL 
Uyirthaathukkal means “Life force” Vatham, Pitham, Kabam, which are the 
humours responsible for the creation, preservation, and desdruction of human body and 
health. When they are in the state of equilibrium in the ratio (1:1/2:1/4) in which they exit 
our body remains in a healthy state, but in case of any disturbance in this ratio leads to 
diseased conditions. 
 
 
VATHAM 
Vatham represents the elements Air & Space.It is responsible for all movements of mind, 
and body. Motor and sensory activities are governed by vatham. 
 
 
S.No. Vatham Physiological function Features in Saganavatham 
1 Pranan 
Inspiration and expiration 
responsible for sneezing coughing 
and belching 
Not affected 
2 Abanan Act with downward movement 
Affected constipation 
present. 
3 Viyanan 
Helps in various movements of 
body, responsible for sensation 
Affected Restricted neck 
movements radiating pain in 
shoulder and arm with 
tingling sensation. 
4 Udhanan 
Regulates the higher functions of 
brain.  Responsible for 
physiological reactions like 
hiccough and vomiting 
Not affected 
5 Samanan Regulates all other vayus 
Affected Due to others types 
of vatham 
6 Nagan 
Responsible for intelligence helps 
in opening and closing of eyes 
Affected in aged pateints.  
Acuity of vision is 
deminished. 
7 Koorman 
 
Responsible for lacrimation.  
Helps in visualization of all things 
of world. 
 
Affected in aged patients.  
Acuity of vision is 
deminished. 
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8 Kirukaran 
Increase salivation in oral cavity 
and mucosa secretion in nasal 
cavity, Increase appetite and helps 
in concentration. 
Affected (Lack of 
concentration) 
9 Thevathathan 
Responsible for laziness. Rotation 
of eyeballs. 
Affected (Sleeplessness 
present due to pain). 
10 Thananjeyan Responsible for tinnitus oedema.  
 
PITHAM: 
Pitham is located in urinary bladder, heart, head, umbilicus, pinkalai, piraanan, 
abdomen, stomach, sweat, blood, eye and skin. 
It is classified in to five type. They are 
 
S.No. Pitham Physiological function 
Features in 
Saganavatham 
1. Anarpitham 
Digests all the ingested 
particles. 
Affected (Indigesion  
present) 
2. Ranjagapitham 
Increases the blood and 
gives blood colour 
Affected (Anaemia 
present) 
3. Saathagapitham 
Makes the work to 
complete what mind 
thinks to do 
Affected neck pain and 
restricted movement 
4. Prasagapitham Gives colours to skin Not affected 
5. Aalosagapitham 
Responsible for clear 
vision 
Affected in old age 
peoples. 
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KABAM: 
Kabam is located is samaanan, semen, fat, bonemarrow, nose, chest, bones, brain, large 
intestine, stomach and pancreas. 
It is divided into five types they are 
S.No. Kabam Physiological function 
Features in 
Saganavatham 
1. Avalambagam Controls other 4 types of kabam 
Affected (santhigam 
affected) 
2. Klethagam Moistens the food Not affected 
3. Pothagam Helps to know the taste Not affected 
4. Tharpagam Gives cooling effect to the eyes 
Affected ( burning 
sensation of eye present) 
5. Santhigam Gives lubrication to joints 
Affected (pain in cervical 
region) 
 
6. UDAL THAADHUKKAL:- 
There are seven udal thaadhukkal in human body they are: 
1. Saaram  - it strengthens the body and mind 
2. Seneer  - it gives power, knowledge and boldness to the mankind 
3. Oon  - it gives a structure and shape to the body and is responsible    
                                               for the movement of the body 
4. Kozhuppu - it lubricates the joints and facilitates their functions 
5. Enbu - it protects the all internal organs and gives structure to the body 
6. Moolai - it is present in the bones and gives strength 
7. Sukkilamor Suronidham - mean for reproduction 
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7. GNAANENCHIRIYANGL:- 
The five gnnaanenchiriyangal are:- 
1. Mei – feels all types of sensations 
2. Vai – for knowing taste 
3. Kan– meant for vision 
4. Mookku– for knowing the smell 
5. Sevi – for hearing 
 
8. KANMEN DHIRIYANGAL:- 
The five kanmendhiriyangal are: 
1. Kai – majority of normal noses done by kal 
2. Kaal – for walking 
3. Vaai– for speaking 
4. Eruvaai – for defecation 
5. Karuvaai – for reproduction 
 
9. THINAIGAL:- 
Study five lands is very much needed, as some diseases are common in the particular lands. 
 
1. Kurinji  – mountain and its surroundings, kabanoigal and liver  
                           diseases are common. 
2. Mullai  – forest and its surroundings,pithanoigal, vaadhanoigal, liver  
                           diseases are Common. 
3. Marudham  – field and its surroundings, safest place to maintain good  
                           health. 
4. Neidhal       – sea and its surroundings, vaadha diseases and liver enlargement  
                            are common. 
5. Paalai  – desert and its surroundings, vaadha, pitha, kabanoigal are    
                           common. 
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10. PARUVANKAALANGAL:- 
A year is classified into six seasons, each constituting two months 
They are, 
1. Kaarkaalam  –  aavani and purattasi 
2. Koodhirkaalam  –  iyppasi and kaarththigai 
3. Mupanikaalam  –  maargazhi and thai 
4. Pinpanikaalam –  maasi and panguni 
5. Elavenirkaalam –  chithirai and vaigaasi 
6. Mudhuvenirkaalam –  Aani and Aadi 
 
Some of the diseases, during a particular season are commonly prevalent and study of it 
will also be much useful to diagnose. The final diagnosis is confirmed by summarizing 
all the clinical findings observed by the above methods. 
DIFFERENTIAL DIAGNOSIS  
                   These are certain other vatha disease which resembles the clinical signs and 
symptoms of ceganavatham. ceganavatham must be differentiated from such disease. 
They are 
1. Kumbavatham 
2. Kandakiragavatham 
3. Paanikambavatham 
 
1.KUMBA VATHAM: 
“                      
                        
                         
                         
                        
                         
                      
                     ”. 
     -                 
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The clinical features are 
1. Pain in shoulder and upper limbs, 
2. Burning sensation in the chest and eyes, 
3. Twitching over the region of scalp, 
4. Lower abdominal pain 
 5. Glossitis 
 
2. KANDAKIRAGA VATHAM 
        “                           
                         
                             
                        
                           
                              
                              
                         ”. 
 -                 
The clinical features are, 
1. Pain in the throat, chest and occipital region 
2. Breathing through mouth, backache, sweating on face. 
 
3. PAANIKAMBA VATHAM: 
“                          
                   
                        
                          
                          
                          
                          
                       ”. 
 -                 
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 The clinical features are 
1. Anorexia 
2. Tingling sensation and numbness of upper limbs 
3. Tremors found in upper limbs 
4. Sleeplessness 
5. Dryness all over the body 
 
MUKKUTRA VERUPAADUGAL (PATHOGENESIS): 
1) Any one or other aetiological factors vitiate vaadha vitiated first. 
2) Then paitham and kabam are also affected which are in three Dhosha equilibrium. 
3) And then vaayus, udalkattugal and other structures are also affected. When 
vaadham is vitiated, body weakness, constipation, Diminution of Immunity 
Giddiness and sleeping disturbances are appeared. 
4) In pitham  
Apitham-Anorexia, Ranjagapitham-low haemoglobin level, Alosagapitham-
Diminished vision, Saadhagapitham-Difficulty to use the neck and upper limbs are 
affected. 
5) In kabam  
Avalambagam- Cough, disturbances of the kabams, Tharpagam- Burning sensation 
of the eyes Sandhigam- Pain in neck and shoulder joint are affected. 
6) In vaayus  
Praanan- cough, Abaanan- constipation, Udhaanan- cough, Viyaanan- Numbness, 
tingling sensation, pain and stiffness in neck, pain upper limbs, Samaanan- 
Disturbances of other vaayus, Naagan- Diminished vision, Kirugaran- Sleeping 
disturbances are affected. 
7) In udal kattugal  
Saaram- Tiredness, anorexia, mental depression, Senner- Anorexia, 
lowhaemoglobin level, Oon- Pain and stiffness in neck , muscle wasting, pain in 
upper limbs, Kozhuppu- Immobilisation and crepitation of neck, difficulty to raise 
the upper limbs, Enbu- Osteophytic formation, pain in neck and upper limb, 
Moolai- Tiredness heaviness of the body are affected. 
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8)  In other structures 
 Nerves   - Pain in neck and upper limb 
           Arteries - Giddiness, mental depression and other connective tissues are also  
                          affected. 
 
LINE OF TREATMENT: 
 The anti vaatha drugs both internal and external application is given to relieve the 
symptoms and strengthen the affected parts. 
 Theraiyar processes like kizhi, ottradam and thattudhal are also applied with 
above medications for better and quick response.  
 INTERNAL MEDICINE: 
Pooranathi chooranam (800mg-1000mg)  (twice daily) for 48 days 
 EXTERNAL MEDICINE: 
Vali kuthaluku ulli ennai (external application only) 
 OTTRADAM: 
Ottradam is one of the supporting therapy for pain management. 
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3.2. REVIEW OF LITERATURE –MODERN ASPECT 
THE ANATOMY 
Vertebral column: 
Our body skeletal system is divided into axial and appendicular skeleton sections. 
Cranium, vertebral column, ribs and sternum constitutes the axial skeleton. 
The vertebral column forms back bone of the body. It is made up of 33 pieces of 
vertebrae and intervening intervertebral disc. Length is about 60-70 cm. The vertebral 
columns which lodges and protect the spinal cord, its meanings in a canal within it is 
called as vertebral canal. It supports the body weight and transmits it to the ground 
through the lower limbs. 
 The segments can be divided into  
Cervical   - 07 
Thoracic   - 12 
Lumbar   - 05 
Sacral    - 05 
Coccygeal   - 04 
The general features of the vertebrae: 
 The Vertebrae can be divided into two parts. Vertebral body (ventral part), 
Vertebral arch (dorsal part). 
 Vertebral bodies are cylindrical and large in size. The vertebral arch has two 
pedicles, seven processes and two lamina. The lamina are vertical plate like structures 
fuses together to form spinnus process. The articular  processes are four in number, 
bearing the articular facts and articulate with the adjacent vertebrae. Transverse processes 
project laterally from the junction of pedicle and laminae. In thoracic region they 
articulate with ribs. 
Intervertebral discs: 
 Intervertebral disc are fibro cartilaginous in nature. The central part is avascular. 
They are thicker in lumbar region. 
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The intervertebral disc acts as 
 As a shock absorber. 
 As a spacer: It maintains its height which allows the segmental nerve roots to 
exits each spinal level without compression. 
 As a hydraulic cylinder: Annular fibers serve a containment function to prevent 
the nucleus from bulging or herniating. 
 As a motion unit: The elasticity of the disc allows motion coupling. So that the 
spinal segment can flex, rotate and bend all side. 
Cervical vertebrae: 
 The cervical segment of vertebral column contains 7 vertebrae. 
 The first second and the seventh are atypical and the third to sixth are typical. 
 They are smaller and delicate than the thoracic and lumbar vertebrae. 
 All the cervical vertebrae have a foramen in the transverse process known as 
foramen transversarium.  
Features of Typical cervical vertebrae: 
Body: 
 It is small and oval. Its superior surface is can care transversely with upward 
projecting lips on each side and its inferior surface is saddle shaped. 
Vertebral foramen: 
 It is larger than the body and triangular. 
Vertebral Arch: 
1)       Spine: 
                   It is short and bifid. 
II) Laminae: 
  These are long and narrow being thinner above than below. 
III) Pedicles: 
  These are short and directed downwards from the middle of posterolateral 
Parts of the body. 
IV) Articular facets: 
The superior and inferior articular processes project laterlly at the junction 
of the pedicle and the lamina. 
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V) Transverse process: 
The transverse process lies laterally from the junction of pedicle and 
laminae to end in posterior tubercle. 
The Atypical Cervical vertebrae: 
1. Atlas: 
 It is the first cervical vertebrae it support the heads. It has no body and spine.  It 
has anterior and posterior arch, right and left lateral mass and transverse processes. 
The Posterior aspect bears an oval facet which articulate with dens. Its anterior 
arch bears an anterior tubercle in the anterior aspect. The posterior surface of the 
posterior arch has a median posterior tubercle. The two lateral masses bear an elongated 
superior articular facet for atlanto – occipital joint and an inferior articular facet for 
atlanto – axial joint. 
2. Axis: 
 The axis has a tooth – like process projecting from the body is known as the dens 
or odontoid process. It has circular facet anteriorly articulating with atlas. There are two 
articular facet on either side of the dens on the upper surface of the body. The laminae are 
thick. The spine is large and bifid terminating in two rough tubercle. The transverse 
process is small and represents the true posterior tubercles only. 
3. The seventh cervical vertebrae: 
 It is also known as the vertebral prominence. The transverse process does not 
possess anterior tubercle. The foramen transversarium is small or absent. It transmits 
accessory vertebral vein only. The spine is long and non-bifid. 
 
Joints of the Neck: 
1. Atlanto – occipital joint: 
It is a synovial joint of the condyloid variety. 
Movements: 
 Flexion, Extension, lateral bending. 
      2. Atlanto – axial Joint: 
 It comprises three joints. 
(i) A Pair of lateral atlanto – axial joints. 
(ii) Median atlanto – axial joint. 
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Movement: 
 Rotatory movements around a vertical axis occur in this joint. 
      3. The unco vertebral Joint: (LUSCHKA’S JOINT) 
 Luschka’s Joints are not true synovial Joint. Which develop as a result of 
degenerative changes in the edges of the disc in early adult. Luschka’s Joints are 
important because 
                                 (a) They are important site of osteophyte formation. 
   (b) The ostrophytes may compress the cervical nerves. 
Blood supply of the Vertebral column: 
 The vertebrae and longitudinal muscles attached to them are supplied by 
segmental arteries. The arteries give multiple small branches to the vertebral bodies. The 
extensor muscles of the neck are supplied by the occipital the deep cervical and the 
transverse cervical arteries. 
Venous drainage: 
 The internal vertebral venous plexus lies within the vertebral canal, but outside 
the spinal dura. It received tributaries from  
 (i) The Vertebrae through the basilo vertebral veins. 
 (ii) The meninges and the spinal cord. 
 
Palpable parts of cervical vertebrae: 
i. The transverse process of C1 through the anterior border of sternocleidomastoid  
immediately below the tip of the mastoid process. 
ii. The spine of C2 is in the nape of the neck 5cm below the external occipital 
protuberance. 
iii. The spine of C7 Where the collor bone crosses the posterior medium line of the 
neck. 
Movements of the Vertebral column: 
 The greater thickness of the disc in the cervical region compared with thoracic 
region is associated with the greater individual range of movements occurring in those 
regions. 
 Flexion, Extension, lateral flexion and rotation are possible in vertebral column. 
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MUSCLE AND NERVE SUPPLY INVOLVED IN MOVEMENTS: 
Movements Muscles Nerve Supply 
Flexion 
Sternocleidomastoid Accessory ventral rami of cervical 
spinal nerves C2, C3, C4 
Longus Capitis Cervical Ventral rami C1-C3 
Longus coli Cervical ventral rami C2-C6 
Rectus Capitis anterior C1 Ventral Ramus 
Extension 
Trapezius Accessory Nerve 
Erector spinae Dorsal rami 
Rectus Capitis posterior 
major and minor 
Dorsal Rami C1 
Oblique capitis superior C1 – Dorsal ramus 
Lateral 
flexion and 
rotation 
Scalene Cervical ventral rami C3-C8 
Sternocleidomastoid Acessory, ventral rami of cervical 
spinal nerves C2,C3,C4. 
Rectus Capitis C1 – ventral ramus 
Splenius Cervical dorsal ramus. 
Longus coli Cervical ventral rami C3-C8 
Levator scapulae Cervical ventral rami C3,C4,C5 
Longismus Obliques 
Capitis superior and inferior 
C1 Dorsal ramus 
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CERVICAL SPONDYLOSIS 
 
DEFINITION 
 Cervical spondylosis is a disorder characterised by degenerative changes in 
intervertebral disc, with subsequent changes in the bones and soft tissues.  Spondylosis is 
usually asymptomatic. Symptoms are usually manifested of encroachment of local neural 
elements such as cervical nerve roots, spinal cord, vertebral artery (or) sympathetic 
nerves 
 
EPIDEMIOLOGY  
Cervical spondylosis is the most frequent cause of spinal cord disturbance in 
patients older than 55 years. 
On the basis of radiological findings, 90% of men older than 50 years and 90% of 
women older than 60 years have evidence of degenerative changes in the cervical spine. 
 Both sex are affected equally. Cervical spondylosis usually starts earlier in men 
than women. 
 
LOCATION: 
             Generally the C5 & C6 roots are most commonly affected by cervical 
spondylosis as a result of increased mobility at the C5 - C6 & C6 – C7 levels. 
              Acute disc lesions are seen most often at the C7 level followed by C6 level. 
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AETIOLOGY 
1. Degenerative Causes 
There are primary and secondary. 
a) Primary –Senility 
 Genetic factors 
 Metabolic factors 
 Manual Labour 
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b) Secondary – Osteo arthritis 
 Rheumatoid arthritis 
 Metastatic carcinoma 
 Lymphoma of spine 
 TB spine 
2. Trauma 
 Automobile accident with whiplash injury 
 Atheletic injury 
 Sudden jerk on the arms during falling down 
 Disc prolaps or previous injury 
3. Occupational cause 
4.    Hereditary factors 
 Congenital narrowing of the cervical spinal canal. 
 Segmental defets – Hemi vertebra, Fushed Vertebrae. 
5.  Acquired narrowing of cervical spinal canal due to  
 Osteophytes 
 Ossified posterior longitudinal ligament. 
 Facet joint hypertrophy (results foraminal stenosis and compression of 
root of radicular artery). 
 Hypertrophied ligamentum flavum (compress the cord during extension). 
 
PATHOPHYSIOLOGY 
 Intervertebral discs lose hydration and elasticity with age and these leads 
to cracks and fissures.  The surrounding ligaments also lose their elastic 
properties and develop traction spurs.  As the disc space narrows, the 
annulus bulges and facet override.  This change, in turn, increase motion 
at that spinal segment and further hastens the damage to the disc, annulus 
fissures and herniation may occur.  Acute disc herniation may complicate 
chronic spondylotic changes. 
 As the annulus bulges, the cross sectional area of the canal is narrowed.  
This effect may be accentuated by hypertrophy of the facet joints 
(posterioly) and of the ligamentum flavum, which becomes thick with age.  
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Neck extension causes the ligaments to fold inward, reducing the 
unterioposterior (AP) diameter of the spinal canal. 
 As disc degeneration occurs, the uncinate process ovverrides and 
hypertrophies compromising the ventrolateral portion of the foramen.  
Facet hypertrophy decreases the dorsolateral aspect of the foramen.  This 
change contributes to the radiculopathy that is associated with cervical 
spondylosis.  Marginal osteophytes begin to develop. 
 
PATHOLOGY 
 The early changes to be erosion and flaking of cartilaginous surface with advance 
of disease. Cleft appear within the cartilage at the right angles to the surface, these claft 
may penetrate to the subchondral bone producing cartilage fibrillation. Sometimes 
fragment of cartilage break off to create joint mice. This result is growth of blood vessels 
from the subchondral bone which is dense, smooth, glittering, to ivory. This is known as 
eburnation. The loss cartilage accounts for the thinning of joint space which is seen radio 
graphically. 
 
Osteophyte development from margin of articular cartilage may extend to 
ligament and capsular attachments. These are called “Bony spurs” of OA. These bony 
spurs accounts for nodules known as Heberden’s nodes. 
 
Common clinical syndromes associated with cervical spondylosis include the 
following:- 
1. HEAD ACHE 
          Head ache is a common symptom. It’s usually located in occipital region.  
2. CERVICAL PAIN 
 Chronic sub occipital head ache may be present. 
 Pain may radiate to the occipital, shoulder, scapula (or) arm. 
 The pain, which is worse when the patient is in certain position, can interfere with 
sleep. 
 
3. AUTONOMIC SYMPTOMS 
Vertigo, flushing, tinnitus, visual blurring are present. These are mediated by sympathetic 
disturbance to the sinuvertebral nerves from stellate ganglion. 
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4. CERVICAL RADICULOPATHY 
Compression of Cervical nerve roots leads to ischemic changes that cause 
sensory dysfunction (Radicular pain) and motor dysfunction (weakness). Radiculopathy 
most commonly occurs in persons aged 40-50yrs. An acute herniated disc or chronic 
spondylotic changes can cause cervical radiculopathy and myelopathy. The C6 root is the 
most commonly affected one because of the predominant degeneration of the C5-C6 
interspace. The next common sites are at C6-C7. There is also referred pain and 
tenderness along the medial border of the scapula. 
 
5. CERVICAL MYELOPATHY 
 It  may be precipitated by a large central disc herniation but is more commonly 
the result of spondylotic changes superimposed on a congenitally narrowed canal. 
Dorsomedial herniation of disc and the development of transverse bony bars or posterior 
osteophytes may results alone or in combination with pressure on the spinal cord or the 
anterior spinal artery which supplies the anterior 2/3 of the cord. 
 
It has an insidious onset, which typically becomes apparent in persons aged 50-60 years.  
 Upper motor neuron signs develop in the limbs with spasticity of the legs. 
 Sensory loss in the upper limbs is common. 
 Tingling and numbness with progressive clumsiness. 
 Involvement of the sphincter is unusual at presentation. 
 
THE SITE OF SENSORY DISTURBANCES WITH INDIVIDUAL 
ROOT 
 
Nerve root  Disc level Symptoms 
C3 C2-C3 Pain and numbness in the back of the neck mastoid process, and pinna of ear. 
C4 C3-C4 Pain and numbness in the back of the neck, levator scapulae and anterior chest. 
C5 C4-C5 Pain in the neck,  Tip of the shoulder, anterior arm, numbness over middle of the body, deltoid muscle. 
C6 C5-C6 
Pain in the neck, shoulder, medial border of the scapula, lateral 
arm, dorsal forearm, numbness in tip of thumb or on dorsum of 
hand over first dorsal interosseus muscle. 
C7 C6-C7 Pain in the neck, shoulder, medial border of scapula, lateral arm, dorsal forearm, sensory change in index and middle finger. 
C8 C7-T1 Pain in the neck, medial border of scapula, medial aspects of arm and forearm. Sensory change in the ring and little fingers.  
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THE MOTOR SYMPTOMS AND SIGNS 
(INCLUDING REFLEXES) 
Nerve Root Disc level Weakness-Reflex change 
C3 C2-C3 
Not readily detectable weakness or reflex change except by 
EMG. 
C4 C3-C4 
Not readily detectable weakness or reflex change except by 
EMG. 
C5 C4-C5 
Weakness of extension of arm and shoulder particularly 
above 90o,wasting of deltoid muscle ,no reflex change.  
C6 C5-C6 Weakness of biceps muscle, diminished triceps reflex. 
C7 C6-C7 Weakness of triceps muscle, diminished triceps reflex. 
C8 C7-T1 
Weakness of triceps and small muscles of hand. No reflex 
change. 
 
PHYSICAL EXAMINATION 
1. Spurling sign 
Radicular pain is exacerbated by extension and lateral bending of the neck toward 
the side of the lesion. Which result in further foraminal compromise. 
2. Lhermitte’s sign 
The generalized electric shock sensation is associated with neck extension. 
3. The elbow flexion test 
           Fully flex the elbow and observe for ulnar nerve distribution. 
4. Shoulder abduction test 
Relief of cervical radiculopathy by abduction. 
5. Phalynx wrist flexion test 
 Full passive flexion of the patient’s wrist for 30-60 seconds and looking for 
reproduction or worsening of worsening of finger dysthesiasis 
6. Adson’s test 
 Turns his head to the involved side raises the chin and holds a deep inspiration 
and while the ipsilateral radial pulse is palpated with the arm slightly abducted from the 
side if pulse diminishes test positive for thoracic outlet syndrome. 
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7. Roo’s test 
            The patient is asked to abduct the shoulder 900, flex the elbow 900 and open & 
close the hands slowly for 3 minutes. 
i) Hand pallor 
ii) Diminished pulse 
iii) Ulnar dysthesias 
If these are positive suggest thoracic outlet syndrome. 
Complications 
1. Pseudo arthrosis 
2. Graft displacement. 
3. Neurological injury 
 
PATHOLOGIES THAT MIMIC CERVICAL SPONDYLOSIS 
1. Hereditary spastic paralysis 
2. Amyotropic lateral sclerosis 
3. Intrinsic & Extrinsic neoplasia 
4. Multiple neoplasia 
5. Spinal infarction 
6. Thoracic outlet syndrome 
7. Vitamin B12 deficiency 
 
INVESTIGATION: 
     1. Plain – x ray of cervical spine antero posterior and lateral views. Intervertebral 
disc space narrowing 
 Osteophytic  changes 
 Altered  Lordosis 
 Degeneration in facet and vertebral joints. 
 Foraminal stenosis, central stenosis. 
 Sclerosis in the vertebrae. 
 
2. MRI -  (MAGNETIC RESONANCE IMAGING: 
To asses cervical canal diameter, to find out severity of the compression 
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3. CT – SCAN (Computerized Tomography) 
 Confirms degenerative changes 
 May demonstrate posterior osteophytes and disc herniation. 
4. CT – MYELOGRAPHY: 
 Useful for localization of cord compression 
5. EXAMINATION OF CSF 
 Very high level of protein. 
INSTRUCTION: 
 Do not getting look down to read (or do any other work). Bring the reading 
materials to the eye level. 
 All the neck movements can be performed with practice, by using trunk 
movements. 
 While lying on sides, head should be in neutral position. 
            Use low level pillow supporting the head and neck. Pillow line up to the shoulders  
            level.  
TREATMENT 
The treatment includes 
 
1. Physiotherapy with short wave diathermy to the neck, 
2. Graded cervical traction may help to relieve pressure on the nerve roots 
3. Analgesics. 
4. When the pain is controlled the patient is taught shoulder bracing and neck 
exercises.  
5. In the acute painful stage, a cervical collar is prescribed.  
6. If definite bony ridges are demonstrable in cases with cord compression surgery 
to relieve pressure is indicated. 
 
   
REVIEW OF LITERATURE – DRUG REVIEW 
40 
 
3.3. REVIEW OF LITERATURE –DRUG REVIEW 
INTERNAL MEDICINE 
The drug taken for the present study is “POORANATHI CHOORANAM” (PC) from the 
Siddha literature AGATHIYAR 2000 3
rd
 PART. Following is the review about the drugs 
used in this formulation.  
The literature poem of the drug POORANATHI CHOORANAM  is given below, 
                ல               
           ல              
                ல        
            ல                     
                     
                          
                            
                    
இந்துப்பைருங் காொங்கரு வௐப்ைின் தண்டு 
  தனு வே ௉ங்கடுக்காய் ௐககக்கிரு க௏ஞ்சு 
முந்திொ ௉ருந்துகள் க்ந்து பைாடிபகாண்டு 
முதர்ௐாத வுடல்வதேில் பெய்ொி்ிடுைித்து 
ௐந்தவுடல் வேத்தும் பதண்பெொனு ைாேம் 
ௐாங்குபௐரு கடிொ௎வுெீங்கிடு வொபொல்்ாம் 
ௐிந்த௉்ர் கின்ௌபூோெ ௐாதிதின்ே 
ௐி௎ங்குப௉ய் யுட்ங்கள்ௐ ௎ங்க௎ிடு வ௉ற்வௌ 
 
 
REVIEW OF LITERATURE – DRUG REVIEW 
41 
 
 
 
INGREDIENTS 
GROUP I: 
1.           (Trianthemaportulacastrum)       
2.            (Goat’s milk)     
3.       ல        (Phyla nodiflora)                    
GROUP II: 
1.            (Caesalpiniabonduc)  
2.         (Zingiberofficinale) 
3.         (Piper nigrum)   
4.     ல      (Piper longum)             
5.             (Pimpinellaanisum) 
6.          (Cuminumcyminum)  
7.             (Ferula asafoetida) 
8.        (Trachyspermumammi)               
9.        ல        (Murrayakoenigi)              
10.              (Terminaliachebula)                      
       11.         (  Rock salt)     
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INTERNAL MEDICINE 
1.        : 
GENERAL PROPERTIES OF SAARANAI: 
KINGDOM   : Plantae 
DIVISION   : Angiosperms 
CLASS   : Dicotyledons 
SUBCLASS   : Caryophyllidae 
ORDER   : Caryophyllales 
FAMILY   : Aizoaceae 
GENUS   : Trianthema 
SPECIES   : T.portulacastrum 
BOTANICAL NAME :  Trianthema protulacastum 
ENGLISH NAME   : Horse purslane 
PART USED   : Roots, leaves 
CHEMICAL CONSTITUENT : Trianthenol, methoxybenzaldehyde 
ACTION :    Alexiteric, Analgesic, Laxative 
 
SUVAI-THANMAI-PIRIVU :  Kaipu- Veppam- Kaarpu 
 
USES : The root is administrated for  Jaundice, Dropsy, Ascites, Rhehematism 
 
2.          
        
           “                            
                      -          
                           
                    .” 
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KINGDOM                : Animalia 
PHYLUM          : Chordata 
CLASS                 : Mammalia 
ORDER                     : Artiodactyla 
FAMILY                   : Bovidae 
GENUS                     : Capra 
SCIENTIFIC NAME : Capra aegagrushircus 
ENGLISH NAME     :  Goat 
CHEMICAL CONSTITUENTS  : Calcium, iron, magnesium and phosphorus 
ACTION: Immuno - modulatory, anti-inflammatory 
 
MEDICINAL USES: 
1. Goat’s milk can help to build bone density, boost immunity against diseases 
and protect against allergies. 
2. It help support healthy digestion, lower risk of diabetes, support weight, 
prevent fat loss and reduce high blood pressure. 
3.      ல: 
       :: 
“                                   
                    -      
                              
                       ”. 
-               
GENERAL PROPERTIES OF PODUTHALAI: 
KINGDOM  : Plantae 
DIVISION   : Angiosperms 
CLASS   : Dicotyledons 
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SUBCLASS    : Asteridae 
ORDER    : Lamiales 
FAMILY    : Verbenaceae 
GENUS    :   Phla 
SPECIES    : P.nodiflora 
BOTANICAL NAME :  Phlanodiflora 
ENGLISH NAME   :  Purple lippa, Turkey tangle frog fruit. 
PART USED    : Leaves, fruits, roots 
CHEMICAL CONSTITUENT :  Lippoflorin A, Nodifloridin A, Tannin 
ACTION :  Demulcent, Deodrant, Diuretics, Astringent, Tonic 
 
SUVAI-THANMAI-PIRIVU : Kaippu, Veppam, Kaarpu 
 
USES: Hook worm infestation, used to relieve fever, cough and cold. 
4.        : 
       : 
“                             
                  -        
                       
                      ”. 
                                        -               
GENERAL PROPERTIES OF KAZHARCHI KAI: 
KINGDOM    : Plantae 
DIVISION    : Angiosperms 
CLASS    : Magnoliopsida 
SUBCLASS    : Rosidae 
ORDER    : Fabales 
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FAMILY    : Fabaceae 
GENUS    :   Caesalpinia 
SPECIES    : C.bonduc 
BOTANICAL NAME : Caesalpinia bonduc 
ENGLISH NAME : Bonduc- Nut, Moloucca Bean, Physic nut 
PART USED: Seed, leaves, bark, root 
CHEMICAL CONSTITUENT : Caesalpinianone, methylcaesalpinianone, hematoxylol,  
                                                        stereochenol A, acetylloganic acid 
ACTION :  Deobstruent, emmenagogue 
 
SUVAI-THANMAI-PIRIVU: Kaippu- Veppam- Karppu 
 
USES: It is used to cure fever, headache and chest pain 
            Used as a tonic for jaundice, diarrhoea and skin eruption 
5.   : 
       :: 
 
“                                
                   -      
                            
                  ” 
     -               
 
GENERAL PROPERTIES OF CHUKKU: 
 
KINGDOM     :  Plantae 
 
DIVISION     :  Angiosperms 
 
CLASS     :  Monocots 
   
SUB CLASS    :  Commelinids 
 
ORDER    :   Zingiberales 
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FAMILY    :   Zingiberaceae 
 
GENUS    :   Zingiber 
  
SPECIES    :  Z .offcinale 
 
BOTANICAL NAME:   Zingiber officinale 
 
PARTS USED :  Root 
 
CHEMICALCONSTITUENT: zingerone, shogaols and gingerols with[6]-gingerol(1- 
                                                      [4'-hydroxy-3'-methoxyphenyl]-5-  hydroxy-3-decanone 
 
ACTION :  Stimulant, Stomachic,Carminative. 
 
SUVAI-THANMAI-PIRIVU : Karpu– Veppam– Karppu  
 
USES: 
Nausea, heart burning, bloating or pain associated with various ailments.  
 
6.   : 
       : 
“                           
                  -        
                           
             ”.  
                                        -               
 
“                            
                        -       
                                  
                  ”. 
                                        -               
 
 
GENERAL PROPERTIES OF MILLAGU: 
KINGDOM  :   Plantae 
DIVISION  :   Angiosperms 
CLASS  :   Magnoliids 
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SUBCLASS  :   Magnoliidae 
ORDER  :  Piperales 
FAMILY  :   Piperaceae 
GENUS  :   Piper 
SPECIES  :   P. nigrum 
BOTANICAL NAME :  Piper nigrum 
 
ENGLISH NAME :  Black pepper  
 
PART USED : Seed, creeper 
 
CHEMICAL CONSTITUENTS: A volatile alkaloid piperine or pipirine 5-9%,  
                                                         piperidine or piperidin 5%, abalsamic volatile  
                                                         essential 1-2%, fat7%Mesocarp contains chavicin,  
                                                         a balsamic volatile oil, starch, gum.  
 
SUVAI- THANMAI- PIRIVI :Kaippu, kaarppu- Veppam- Kaarpu 
 
ACTIONS: Carminative , Pungent, Antiperiodic , Analgesic , Anti inflammatory,  
                     Anti – oxidant. 
 
USES: It is useful in dyspepsia and flatulence in doses of 10-15 grains of the powder and  
            in haemorrhoids in form of confection. It is a useful ingredient in tooth powder.  . 
 
7.    ல  
 
       : 
“                             
                    -        
                               
                  ”.. 
-           
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GENERAL PROPERTIES OF THIPPILI: 
 
KINGDOM   :   Plantae 
 
DIVISION   :   Angiosperms 
 
CLASS   :   Magnolids 
 
ORDER   :   Piperales 
  
FAMILY   :   Piperaceae 
 
GENUS   :   Piper 
 
SPECIES   :   P.longum 
 
BOTANICAL NAME :   Piper longum 
 
ENGLISH NAME  :   Long pepper 
 
PART USED   :  Fruits and roots 
 
CHEMICAL CONSTITUENTS :  Guineensine, Pipernonaline, Pellitorine, Piperine,  
           Pipermonaline, Brachyamide A and B from fruits  
           and Piperlongumine and Sesamine from roots. 
 
ACTIONS: Analgesic, Carminative, Stimulant Immunomodulator, Anti – oxidant,  
                    Anti – inflammatory 
 
SUVAI-THANMAI-PIRIVU: Enippu, Veppam, Enippu 
 
USES:  Root and fruit decoction used for treating gonorrhoea, menstrual pain, RTI, TB,   
             sciatica, hemiplegia, arthritis. 
 
8.         
       : 
“                               
                   -       
                                
                 ”. 
-              . 
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GENERAL PROPERTIES OF PERUNJCHIRAKAM: 
KINGDOM   :   Plantae 
DIVISION   :   Angiosperms 
CLASS   :   Eudicots 
SUBCLASS   :   Asterids 
ORDER   :   Apiales 
FAMILY   :   Apiaceae 
GENUS   :   Foeniculum 
SPECIES   :   F.vulgare 
BOTANICAL NAME :  Foeniculum vulgare 
ENGLISH NAME  :   Fennel, Anise seed 
PART USED   :  Seed, flower, Root 
CHEMICAL CONSTITUENT: Methylchavicol, anisaldehyde, estragole, trans-anethole 
ACTION: Carminative, expectorant 
 
SUVAI-THANMAI-PIRIVU: Manamutankudiyakarppu, Enippu-veppam-karppu 
 
USES: It make it a natural choice to alleviate flatulence and mouthwashes. 
            When it mixed with other oil, aniseed oil provides a good antiseptic. 
9.    : 
       : 
                            
                    -         
                            
                   . 
                                         -           
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GENERAL PROPERTIES OF CHIRAKAM:  
KINGDOM   : Plantae 
DIVISION   : Angiosperms 
CLASS   : Eudicots 
SUBCLASS   : Asterids 
ORDER   : Apiales 
FAMILY   : Apiaceae 
GENUS   :   Cuminum 
SPECIES   : C.cyminum 
BOTANICAL NAME : Cuminum cyminum 
ENGLISH NAME    : Cumin seed  
PART USED    : Seed 
CHEMICAL CONSTITUENT :  α-Pinene, limonene,linalyl acetate 
ACTION: Carminative, stimulant, stomachic, astringent 
 
SUVAI-THANMAI-PIRIVU : Karppu, enippu- thatppam- enippu 
 
USES: It is used for diarrhea, colic abdominal pain, bowel spasm, menstrual problem. 
10.         
       : 
 
“                     
                      
                           
                      
                        
                       
                       
                    ” 
                                                                                      -               
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GENERAL PROPERTIES OF PERUNGAYAM:  
 
KINGDOM   :   Plantae 
 
DIVISION   :   Angiosperms 
  
CLASS   :   Eudicots 
 
SUBCLASS   :   Asterids 
 
ORDER   :   Apiales 
 
FAMILY   :   Apiaceae 
  
GENUS   :   Ferula 
 
SPECIES   :   F.asafoetida 
 
BOTANICAL NAME :   Ferula asafoetida 
 
ENGLISH NAME  :   Asafoetida 
 
PART USED   :   Oleo – gum resin 
 
CHEMICAL CONSTITUENTS: Disulfides, Tri – and Tetrasulfides, Glucuronic acid,  
                                                         Galactose, Arabinose, Umbelliferone, Foetidin, Coumarin 
 
ACTIONS: Sedative, Anti – spasmodic, Anthelmintic, Emmenogogue, Expectorant, 
                     Carminative. 
SUVAI-THANMAI-PIRIVU: Kaippu, Kara karappu- Veppam, Kaarppu 
 
 USES: * It has been used as the remedy for abdominal pain and constipation. 
      * Resin used in the treatment for nervous disorders and spasmodic disorders.  
             * Asafoetida used in sterility, unwanted abortion, premature labour, excessive 
                menstruation, leucorrhoea. 
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11.   : 
       : 
 
“                            
                       –      
                               ? 
                        ”  
                   -               
 
GENERAL PROPERTIES OF OMAM 
 
KINGDOM   :   Plantae 
 
DIVISION   :   Angiosperms 
 
CLASS   :   Eudicots 
 
SUBCLASS   :   Asterids 
 
ORDER   :   Apiales 
   
FAMILY   :   Apiaceae 
 
GENUS   :   Trachyspermum 
 
SPECIES   :   T.ammi 
 
BOTANICAL NAME :   Trachyspermum ammi 
 
ENGLISH NAME  :   Bishops weed 
 
PART USED   :   Seeds 
 
CHEMICAL CONSTITUENTS: Essential oil, Thymol, Carvacrol, α and β – pinene,  
                                                          Camphene, Threonine 
 
ACTIONS: Diuretic, Carminative, Anti – vomiting, Anti – hypertensive, Anti –  
                     spasmodic Anti – oxidant, Anti – inflammatory 
 
SUVAI-THANMAI-PIRIVU :  Kaarpu, Veppam, Kaarpu 
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USES: The seed decoction used in the cases of asthma, anti – dyspnoeic effect,                                   
             cutaneousdisorders, neural and UTI disorders. 
12.          ல: 
       : 
“                         
                      -    
                   !      
                ”.  
  -               
GENERAL PROPERTIES OF KARIVEPPILAI: 
KINGDOM   :   Plantae 
DIVISION   :   Magnoliophyta 
CLASS   :   Dicotyledons 
SUBCLASS   :   Rosidae 
ORDER   :   Sapindales 
FAMILY   :  Rutaceae 
GENUS   :  Murraya 
SPECIES   :   M. koenigii 
BOTANICAL NAME :  Murraya koenigii 
ENGLISH NAME  :   Curry leaves, Sweet neam 
PART USED   :   Leaves, Rib of the leaves (Erkku), Bark, Root. 
CHEMICAL CONSTITUENT :  Cinnamaldehyde, Carbazolealkaloids,Mahanimbine,  
                                                         Girinimbine 
ACTION: Tonic, Stomachic 
 
SUVAI-THANMAI-PIRIVU :  Sirukaarppu- veppam- kaarppu 
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USES:   The leaves, barks, roots used in digestive problem, it has been shown that the  
           leaves increases digestive secretion and relieve nausea, vomiting and indigestion. 
13.      : 
       : 
 
“                            
                   -             
                              
                 ” 
 
”                       
                  -          
                          
                  ”             
 
                                   
GENERAL PROPERTIES OF KADUKKAI: 
 
KINGDOM  :    Plantae 
 
DIVISION  :   Angiosperms 
 
CLASS  :   Eudicots 
 
SUBCLASS  :   Rosids 
 
ORDER  :   Myrtales 
 
FAMILY  :   Combretaceae 
 
GENUS  :   Terminalia 
 
SPECIES  :   T.chebula 
 
BOTANICAL NAME :  Terminalia chebula 
 
ENGLISH NAME    :  ChebulicMyrobalan, Ink nut 
 
 
PART USED    :   Unriped fruit and Galls 
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CHEMICAL CONSTITUENTS: Gallic acid, Chebupentol, Chebulagic acid, Terminoic  
                                                          acid, p-coumaric acid, Tannin(30-32%), Arjunolic acid 
 
ACTIONS: Astringent, Alterative, Carminative, Anti septic, Anti – inflammatory,  
                    Anti – arthritic, Anti – oxidant 
 
SUVAI-THANMAI-PIRIVU :  Kaarpu-Veppam- Enippu 
USES:  
 The powdered fruit act as an astringent and is used in haemorrhoids, dentrifice 
inloose gums, bleeding and ulceration in gums. 
 Fruit decoction used in curing diarrhoea and dysentery. 
 Fruit powder has Anti-ageing activity. 
14.       
 
       : 
 
“                             
                       –          
                               
                ” 
  
“                                 
                     –         
                          
                   “ 
-                   
GENERAL PROPERTIES OF ROCK SALT 
 
CATEGORY    :   Hallide mineral 
 
FORMULA   :   Nacl 
 
CRYSTAL SYSTEM :   Cubic 
 
CRYSTAL CLASS  :   Hexoctahedral 
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IDENIFICATION 
 
FORMULA MASS  :   58.433 g/mol 
 
COLOR   :   Colorless or White 
 
CRYSTAL HABIT  :  Predominantly cubes but also Granular, Fibrous and Compact 
 
FRACTURE   :   Conchoidal 
 
TENACITY   :   Brittle 
 
LUSTER   :   Vitreous 
 
STREAK   :   White 
 
SPECIFIC GRAVITY :   2.17 
 
OPTICAL PROPERTIES :   Isotropic 
 
REFRACTIVE INDEX :   n=1.544 
 
SOLUBILITY  :   Water soluble 
 
ACTIONS: Carminative, Diuretic, Stimulant, Laxative 
USES        : It is used in the treatment for gastritis, indigestion, dental and genital  
                    disorders,  venous ulcers. 
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DRUG REVIEW –EXTERNAL MEDICINE 
1.     :  
       : 
“                          
                     -       
                           
                  ” . 
 -               
GENERAL PROPERTIES OF ERULLI: 
KINGDOM   :   Plantae 
DIVISION   :   Angiosperms 
CLASS   :   Monocots 
SUBCLASS   :   Liliidae 
ORDER   :   Liliales 
FAMILY   :   Lilliaceae 
GENUS   :   Allium 
SPECIES   :   A. cepa 
BOTANICAL NAME :   Allium cepa 
ENGLISH NAME  :   Onion 
PART USED   :   Green leaves, bulbs,  flower, seed 
CHEMICAL CONSTITUENT : Quercetin, fructose, quercetin-3-glucoside, xylose,  
                                                        flavonoids, selenium. 
ACTION: Stimulant, diuretic, expectorant, emmenagogue, rubefacient, demulcent,  
                   aphrodisiac  
 
SUVAI-THANMAI-PIRIVU  :   Kaippu- veppam- karppu 
 
USES : It improves ocular ailments, aid in sleep, heal everything from oral sores, 
lumbago, dysentery. 
REVIEW OF LITERATURE – DRUG REVIEW 
58 
 
2.    :  
       : 
“                                 
                                 
                              
                              ”. 
       -               
GENERAL PROPERTIES OF VASAMBU: 
KINGDOM    :  Plantae  
DIVISION    :   Tracheophyta 
CLASS    :  Magnoliophytina 
ORDER    :   Acorales 
FAMILY    :   Acoraceae 
GENU S    :    Acours 
SPECIES    :    A calamus 
BOTANICALNAME  :    Acorus calamus 
ENGLISHNAME   :     Sweet flag 
CHEMICALCONSTITUENT                :     Teuclatriol,beta-sitosterol, methychavicol,       
                                                                  Cadinane. 
 
PARTUSED    :    Root  
ACTION  :  Germicide, Antihistaminic, Anti-muscarinic, Disinfectant 
SUVAI-THANMAI-PIRIVU  :    Karppu- veppamkarppu 
USES: Fever, asthma, bronchitis, digestive problems 
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3.        : 
       : 
“                           
                   -     
                             
                ”. 
               -           
GENERAL PROPERTIES OF NOCHI: 
KINGDOM   :   Plantae 
DIVISION   :   Angiosperms 
CLASS            :   Eudicots  
SUB CLASS   :   Asteroids 
ORDER   :   Lamiales 
FAMILY    :   Lamiaceae 
GENUS   :   Vitex 
SPECIES   :  V . negundo 
BOTANICALNAME :   Vitex negundo 
ENGLISH NAME  :   Five leafs chaste tree 
PARTS USED  :   Root 
CHEMICALCONSTITUENT :  Casticin,  Isoorientin, Chrysopheno l D,  Luteolin,  
                                                       P-hydroxybenzoic acid and D-fructose. 
 
ACTION: Febrifuge, Expectorant, Diuretic. 
SUVAI-THANMAIPIRIVU:  Kaippu, Thuvarppu – Veppam – Karppu 
USES: Roots and leaves are used in eczema, ringworm and other skin diseases, liver          
            disorders, spleen enlargement, rheumatic pain, gout, abscess, backache. 
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4.          :  
       :  
“                                   
                   -         
                        
                   ”.  
                                          -               
GENERAL PROPERTIES OF THAZHUTHAZHAI: 
KINGDOM   :   Plantae 
DIVISION   :   Angiosperms 
CLASS   :   Eudicots 
SUBCLASS   :   Asterids 
ORDER   :   Lamiales 
FAMILY   :   Lamiaceae 
GENUS   :   Clerodendrum 
SPECIES   :   C.phlomidis 
BOTANICAL NAME :   Clerodendrm phlomidis 
ENGLISH NAME  :   Wind killer 
PART USED   :   Root, Leaves 
CHEMICAL CONSTITUENT :  Flavonoids, glycosides, pectolinaingenin, D-
glucopyranoside 
ACTION :  Alterative, Astringent 
 
SUVAI-THANMAI-PIRIVU :  Kaippu, Thuvarppu- veppam - karppu 
 
USES:  * The pulp obtained from the crushing of the leaves is applied externally on   
                swelling. 
* Root is used to improve body vigor and maintain good health. 
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5.         :  
       : 
“                               
                      -       
                            
                       ”. 
                                            -               
GENERAL PROPERTIES OF VEMBU: 
KINGDOM   :  Plantae 
DIVISION   :   Angiosperms 
CLASS   :   Magnoliopsida 
SUBCLASS   :   Rosidae 
ORDER   :   Spindales 
FAMILY   :   Meliaceae 
GENUS   :    Azadirachta 
SPECIES   :    A. indica 
BOTANICAL NAME :    Azadirachta indica 
ENGLISH NAME  :    Neem tree, Margosa tree 
PART USED : Seed oil, leaves, bark, fruit, root, gum, neem cake 
CHEMICAL CONSTITUENT : Azadirachtin and Nimbin along with triglycerides,  
                                                       Stigmasterol, Campesterol, beta-sitosterol. This oil also    
                                                       contains fatty acids, namely Omega-6, Omega-9,  
                                                       stearic acid and palmitic acid. 
ACTION :   Stimulant, Antiseptic, Insecticide, Anthelmintic, Anti inflammatory 
 
SUVAI-THANMAI-PIRIVU :  Kaippu- Veppam- Karppu 
 
USES:  It is used to be antibacterial, antifungal, antidiabetic, anthelmintic. 
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6.           : 
       : 
“                             
                 -          
                             
                   ”. 
                       
GENERAL PROPERTIES OF AAMANUKU: 
KINGDOM   :   Plantae 
DIVISION   :   Angiosperms 
CLASS   :   Eudicots 
SUBCLASS   :   Rosids 
ORDER   :   Malpighiales 
FAMILY   :   Euphorrbiaceae 
GENUS   :   Ricinus 
SPECIES   :   R communis 
BOTANICAL NAME :   Ricinus  communis 
ENGLISH NAME  :   Castor oil plant 
CHEMICAL COSTITUENTS : Curcin, ricinine (0.55%) and N-demethylricinine  
                                                        flavones glycosides kaempferol-3-O kaempferol-3-O- 
                                                        β-D-glucopyranoside,  
 
PART USED  : leaves, seeds, root 
ACTION: Anti vadha,Galactagogue, anti-oxidant, antihistamic, antiasthmatic, antiulcer,  
                        immunemodulatory, Antidiabetic,  hepatoprotective,  Antifertility, anti  
                        inflammatory, antimicrobial,  
                        
SUVAI – PIRIVU – VIBAVAM Kaippu- Veppam-Karppu 
 
USES:  It is used from ancient time to cure rheumatism, worm infestation, sever  
             constipation and abdominal disorders.  
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7. ey;nyz;nza;: 
       : 
“                              
                 –          
                               
                         ” 
 
-               
GENERAL PROPERTIES OF ELLU: 
KINGDOM   :   Plantae 
DIVISION   :   Angiosperms 
CLASS   :   Eudicots 
SUBCLASS   :   Asterids 
ORDER   :   Lamiales 
FAMILY   :   Pedaliaceae 
GENUS   :   Sesamum 
SPECIES   :   S.indicum 
BOTANICAL NAME :   Sesamum indicum 
ENGLISH NAME  :   Gingeli oil 
PART USED   :  Seed oil 
CHEMICAL CONSTITUENTS : Lignanssesamolin, Sesamin, Pinoresinol, Lariciresinol 
ACTIONS  :   Demulcent, Emollient, Laxative, Nutritive 
SUVAI-THANMAI-PIRIVU  : Inippu, Veppam, Inippu 
MEDICINAL USES: * Calcium, zinc, copper minerals in oil plays an important role in  
                                        growth of bone, healing, regrowth of bone and prevent osteoporosis. 
 
                        *   It can help to reduce the inflammation and discomfort of    
                             various conditions such as gout and arthritis by reducing the    
                             swelling of joints. 
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4.MATERIALS AND METHODS 
 
Approval of the Screening committee and Institutional ethical committee were 
obtained for undertaking the present study.  
The study design and the underlying hypothesis and the rights to withdraw from 
the study at any time were informed orally and in writing to all the participants. A single 
center open clinical trial was undertaken. 
STUDY PLACE  : OPD & IPD of PG department of Varmam, Puramaruthuvam and      
                                       Siddhar Yoga maruthuvam, Govt. Siddha medical college  
                                       attached with  Arignar Anna Hospital for Indian Medicine and    
                                       homoeopathy, 
STUDY PERIOD : 12 Months 
SAMPLE SIZE : 40 patients  
(20 - OP; 20 - IP -10 with trial medicines, 10 with Ottradamalong 
with trial medicine. 
TRIAL DRUGS:  
 
4.1 INTERNAL MEDICINE: “POORANATHI CHOORANAM” 
(Reference : AGATHIYAR 2000 3
rd
Part ) 
SOURCE OF RAW DRUGS:  
The required raw drugs were purchased from authorized centers.The raw drugs 
and Mineral drugs were authenticated by the PG Gunapadam & Department of Medicinal 
Botany, GSMC, Chennai. Then the medicine was  purified and prepared in Gunapadam 
laboratory of Government Siddha Medical College, Chennai-106. 
 
They were subjected to screening test and documented using screening Performa. 
40 patients who fulfilled the inclusion criteria were subjected to protocol comprising 
selection criteria, clinical assessment, Siddha assessment, laboratory investigations, and 
diagnosis and treatment aspect. 
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LIST OF INGREDENTS:    
GROUP 1: 
1.         (Trianthema portulacastrum)     - 16palam [560gm] 
2.        (Goat’s milk)        - 1 padi [1520ml] 
3.              (Phyla nodiflora)          - 2 padi[3040ml] 
 
 GROUP 2:     
1.          (Caesalpinia bonduc)      - 9 palam [315gms] 
2.     (Zingiber officinale)           - 2kazhanju [10.2gms] 
3.      (Piper nigrum)       - 2kazhanju [10.2gms] 
4.        (Piper longum)               - 2kazhanju [10.2gms] 
5.            (Pimpinella anisum)   - 2kazhanju [10.2gms] 
6.        (Cuminum cyminum)    - 2kazhanju [10.2gms] 
7.            (Ferula asafoetida)   - 2kazhanju [10.2gms] 
8.       (Trachyspermum ammi)    - 2kazhanju [10.2gms] 
9.                (Murraya koenigi)   - 2kazhanju [10.2gms] 
10.             (Terminalia chebula)           - 2kazhanju [10.2gms] 
      11.       (Rock salt)           - 2kazhanju [10.2gms] 
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MATERIALS REQUIRED: 
GROUP I 
                                   
 
 
 
 
 
சாரணை வவர்    
(Trianthema portulacastrum)                              
      
      
      
      
      
      
      
                                                   
ப ாடுதணல  (Phyla nodiflora) 
ஆட் டுப் ால் (Goat’s milk)                 
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GROUP II 
               
              
              
கழற்சிக்காய்    
(Caesalpinia bonduc)       சுக்கு   (Zingiber officinale)                
மிளகு        (Piper nigrum) திப் ிலி  (Piper longum)                
ப ருஞ்சரீகம்   
(Pimpinella anisum)                    சரீகம்  (Cuminum cyminum)  
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ப ருங்காயம்   (Ferula asafoetida)                       ஓமம்      (Trachyspermum ammi)   
கறிவவப் ிணல ஈர்க்கு   (Murraya koenigi)                 கடுக்காய் வதால்   (Terminalia chebula)  
இந்துப்பு    (Rock salt)                   
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PREPARATION OF THE DRUG: 
1. Procurement/collection of ingredients for the preparation of  Pooranathi 
chooranam. 
2. Purification of ingredients for the above (Agathiar sarakku suthi muraigal) 
3. 560gms of saranaiver was taken and it is boiled in the goat’s milk & 
podudhalaicharu, it was dried in the sunshade. 
4. Then kalarchikai was placed in mud plate and closed with suitable another 
mud plate, seal it with a mud pasted cloth (sellai) and is taken to pudam 
with 25Nos cow dunk cake. After the pudam , remove the outer coat and 
collect the kalarchi seeds and then made in to fine powder. 
5.   Then the balance raw drugs were slightly fried and grind separately using 
a stone mortar and sieved by white cloth. 
6. It was mixed well together with the above mentioned powder and stores it 
in an air tight container.    
DOSAGE       :  Mooviralalavu (1 to 2 gm.) Twice daily for 48 days 
ADJUVENT   :  Honey 
 
POORANATHI CHOORANAM 
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4.2 EXTERNAL DRUG: VALI KUTHALUKU ULLI ENNAI 
(Reference:Oorvasi Iravatha Sitkha Vaithiya Sitkha Pancharathinam) 
INGREDIENTS:  
1. Eerulli(Allium cepa)        - 2 palam (70gms) 
2. Vasambu (Acorus calamus)           - 1palam (35gms) 
3. Nochiver(Vitex negundo)            - 1/2palam (17.5gms) 
4. Thazhuthazhaiver(Clerodendrum phlomoidis) - 1/2palam(17.5gms) 
5. Neem oil (Azadirachta indica)              - 2palam (70gms) 
6. Castor oil (Ricinus communis)                               - 2palam (70gms) 
7. Gingelly oil (Sesamum indicum)                              - 2palam (70gms) 
 
 
 
 
 
 
ஈருள்ளி (Allium cepa)                வசம்பு (Acorus calamus) 
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ப ாச்சி வவர்  
(Vitex negundo)             
தழுதாணழ வவர்  
(Clerodendrm phlomidis)             
       Ntg;ngz;nza;                                              
      (Azadirachta indica)  
ஆமைக்பகண்பைய் 
   (Ricinus communis) 
ey;nyz;nza; : Sesamum 
indicum 
    VALI KUTHALUKU ULLI 
ENNAI         
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METHOD OF PREPARATION: 
1. Procurement/collection of ingredients for the preparation of  Pooranathi 
chooranam. 
2. Purification of ingredients for the above (Agathiar  sarakku suthi muraigal) and 
make in to a Karkam. 
3. This karkam were mixed with the above oils and heat until attains its consistency. 
4. Then the end products is filtered and oil were collected in a dry, clean airtight 
container. 
INDICATION: 
Sagalavali (All type of pain), kuththal, kudaichal. 
 
4.3.THERAPY - OTTRADAM 
 
DEFINITION: 
 
The required plant parts, grains and others are put in a container, fried or boiled or 
heated and then tied in a cloth bag. The bag is put on the affected areas and then gently 
compressed and released in a rhythemic manner for few minutes or till the heat subsides. 
It is also called as Otral. Cold paste can also be used as otral. 
Bronze, Iron, Rod, Sand, Cloth, Mud vessel are also heated and used for fomentation to 
give relief from pain. 
வேப்பம் 
பிண்ணாக்கு 
ஒற்றடம் 
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PROCEDURE: 
• Dried Neemcake are pounded using a stone mortar and powdered. 
• It is slightly fried and tied using a cotton cloth. 
• Then fomentation over the affected area. Repeat the process for 7 times. 
INDICATION: 
   Valinoi, Mupini, Thalaivali, Iyyanoi 
REFERENCES: 
   Gunapadam Mooligai 
METHODOLOGY OF TREATMENT: 
STUDY ENROLLMENT: 
   Patients reporting at the OPD/IPD with clinical features of pain in nape radiating 
to upper limbs, stiffness are chosen for enrollment based on the inclusion criteria. 
   The patients who are enrolled will be informed (Form VI) about the study, trial 
drug, possible outcomes and the objectives of the study in the language and terms 
understandable to them and theinformed consent would be obtained in writing from them 
in the consent form (Form VI).  
   All these patients will be given unique registration card in which the patients 
Registration number of the study, Address, Phone number and Doctors phonenumber etc. 
will be given, so as to report easily should any complications arise. 
   Complete clinical history, complaints, duration, examination findings and 
laboratory investigations -- will be recorded in the prescribed Proforma. 
   Screening Form- I will be filled up: Form –II and Form –III will be used for 
recording the patients history, clinical examination of symptoms, signs and laboratory 
investigations respectively. Patients will be advised to take the trial drug and appropriate 
dietary advice would be given according to the patients’ perfect understanding. 
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CONDUCT OF THE STUDY: 
   For out-patients, the trial drug Pooranathi Chooranam (Int), Vali 
kuthalukuulliennai (Ext) and Ottradam (Therapy) will be given in the Out-patient 
Department of  Varma Maruthuvam, Pura Maruthuvam & Yoga Maruthuvam of GSMC 
attached with AAGHIM. The out-patients will be asked to have a regular follow-up in the 
OP Department once in 7 days. In each and every visit, the clinical assessment will be 
recorded in the prescribed proforma. For IPD patients, trial drug was dispensed daily till 
they get discharge.  The laboratory investigations will be done before and after treatment 
and recorded in the prescribed format. At the end of the trial the patients are advised to 
have follow-up for 2 more months for observing any recurrence. Defaulters will not be 
allowed to continue and will be withdrawn from the study. 
DATA COLLECTION FORMS: 
Required information will be collected from each patient by using following forms: 
FORM I  : Screening and selection proforma 
FORM lI  : History proforma on enrollment 
FORM llI  : Clinical assessment proforma 
FORM lV       : Laboratory investigations proforma  
FORM V  : Consent form 
FORM VI  : Withdrawal form 
FORM VII  :  Patient information sheet 
FORM VIII  : Dietary advice form 
FORM IX  : Adverse reaction form 
INCLUTION CRITERIA: 
• Age      :  between 20-60 years  
• Sex      :  Both male and female 
• Muscle spasms in neck and shoulders  
• Complaint about pain behind the neck in the area of trapezius                                           
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• Radiating pain to the upper limbs 
•  Numbness and weakness in arms, hands and fingers 
• Giddiness  
EXCLUSION CRITERIA: 
• Cervical rib 
• Trauma 
• Spina bifida  
• Cardiac disease 
• Fracture  
• Ankylosingspondylosis 
• Malignancy  
• Pregnancy and Lactation  
• Tuberculosis in spine 
• Adhesive capsulitis 
• Carpal tunnel syndrome 
• Patient with any other serious systemic illness. 
 
WITHDRAWAL CRITERIA 
 Intolerance to the drug and development of any serious  adverse  effect  during the 
period of drug trial.  
 Patient turned unwilling to continue in the course of Clinical trial with any other 
systemic illness.  
ADR REPORTING:- 
      If ADR is reported , patients will be referred to SCRI (Peripheral Pharmacovigilance 
Centre) then the patient is directed to nearest Govt. hospital. 
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THE CLINICAL ASSESSMENT AND OUTCOME WERE ASSESSED BASED 
ON THE FOLLOWING:  
TESTS AND ASSESMENTS  
1. Clinical assessment 
2. Routine investigations 
3. Specific investigations  
1.CLINICAL ASSESSMENT 
 Stiffness of neck 
  Pain in nape of the neck 
  Radiating pain in upper limbs upto the fingers 
 Tenderness 
  Numbness 
 Restriction of movements of neck 
 Giddiness 
Pain assessment scale-visual analog scale 
 
Grade 0 :  No Pain 
Grade 1 -3 :  Mild pain 
Grade 4-6 :  Moderate pain 
Grade 7-10 :  Severe pain 
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GRADATION:  
1. Grade 1 - Fit for all activities and to do the works without support (Normal).  
2. Grade 2 - Mild pain and mild restriction of movements.  
3. Grade 3 - Moderate pain with or without radiation to upper limbs and moderate 
restriction of movements.  
4. Grade 4 - Severe pain with or without radiation to upper limbs and severe restriction of 
movements.  
2. ROUTINE TESTS AND INVESTIGATION:  
INVESTIGATIONS BASED ON SIDDHA SYSTEM  
ENVAGAI THERVU: 
The cases were regarded in a prescribed Proforma prepared on the basis of siddha 
methodology. An individual case sheet was maintained for each case in the outpatient& 
inpatient department. 
BLOOD: 
 Complete blood routine test. 
 TC, DC, ESR, HB and BS(R) 
Renal function test:           
 Blood urea, Serum creatinine 
Liver function test: 
 S.Bilurubin, Alkaline Phosphatase, SGOT, SGPT 
URINE ANALYSIS: 
Albumin, Sugar, Deposit 
SPECIFIC INVESTIGATIONS:  
X- Ray: Cervical spine – AP &Lat view 
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4.4 STANDARDIZATION PARAMETERS 
 
ORGANOLEPTIC CHARACTERS: 
STATE Solid 
APPEARANCE Pale Greenish 
NATURE Fine powder 
ODOR Characteristic odor 
FLOW PROPERTY Dry Free flowing 
 
PHYSICOCHEMICAL EVALUATION: 
Percentage Loss on Drying 
Test drug was accurately weighed in evaporating dish .The sample was dried at 
105
o
C for 5 hours and then weighed. 
Determination of Total Ash 
Test drug was accurately weighed in silica dish and incinerated at the furnace a 
temperature 400 ºC until it turns white in color which indicates absence of carbon. 
Percentage of total ash will be calculated with reference to the weight of air-dried drug. 
Determination of Acid Insoluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of dilute hydrochloric 
acid for 6mins. Then the insoluble matter is collected in crucible and will be washed with 
hot water and ignited to constant weight. Percentage of acid insoluble ash will be 
calculated with reference to the weight of air-dried ash. 
Determination of Water Soluble Ash 
The ash obtained by total ash test will be boiled with 25 ml of water for 5 mins. 
The insoluble matter is collected in crucible and will be washed with hot water, and ignite 
for 15mins at a temperature not exceeding 450ºC. Weight of the insoluble matter will be 
subtracted from the weight of the ash; the difference in weight represents the water 
soluble ash. Calculate the percentage of water-soluble ash with reference to the air-dried 
drug. 
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Determination of Alcohol Soluble Extractive 
Test sample was macerated with 100 ml of Alcohol in a closed flask for twenty-
four hours, shaking frequently during six hours and allowing to stand for eighteen hours. 
Filter rapidly, taking precautions against loss of solvent, evaporate 25 ml of the filtrate to 
dryness in a tared flat bottomed shallow dish, and dry at 105ºC, to constant weight and 
weigh. Calculate the percentage of alcohol-soluble extractive with reference to the air-
dried drug. 
Determination of Water Soluble Extractive 
Test sample was macerated with 100 ml of chloroform water in a closed flask for 
twenty-four hours, shaking frequently during six hours and allowing to stand and for 
eighteen hours. Filter rapidly, taking precautions against loss of solvent, evaporate 25 ml 
of the filtrate to dryness in a tared flat bottomed shallow dish, and dry at 105ºC, to 
constant weight and weigh. Calculate the percentage of water-soluble extractive with 
reference to the air-dried drug. 
 
HEAVY METAL ANALYSIS BY AAS 
Standard: Hg, As, Pb and Cd – Sigma 
Methodology 
Atomic Absorption Spectrometry (AAS) is a very common and reliable technique for 
detecting metals and metalloids in environmental samples. The total heavy metal content 
of the sample was performed by Atomic Absorption Spectrometry (AAS) Model AA 240 
Series. In order to determination the heavy metals such as mercury, arsenic, lead and 
cadmium concentrations in the test item. 
Sample Digestion 
Test sample was digested with 1mol/L HCl for determination of arsenic and mercury. 
Similarly for the determination of lead and cadmium the sample were digested with 
1mol/L of HNO3. 
Standard reparation 
As & Hg- 100 ppm sample in 1mol/L HCl 
Cd &Pb- 100 ppm sample in 1mol/L HNO3 
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TLC AND HPTLC ANALYSIS: 
TLC Analysis: 
Test sample was subjected to thin layer chromatography (TLC) as per 
conventional one dimensional ascending method using silica gel 60F254, 7X6 cm 
(Merck) were cut with ordinary household scissors. Plate markings were made with soft 
pencil. Micro pipette were used to spot the sample for TLC applied sample volume 10-
micro liter by using pipette at distance of 1 cm at 5 tracks. In the twin trough chamber 
with the specified solvent system After the run plates are dried and was observed using 
visible light Short-wave UV light 254nm and light long-wave UV light 365 nm 
 
High Performance Thin Layer Chromatography Analysis 
HPTLC method is a modern sophisticated and automated separation technique 
derived from TLC. Pre-coated HPTLC graded plates and auto sampler was used to 
achieve precision, sensitive, significant separation both qualitatively and quantitatively. 
High performance thin layer chromatography (HPTLC) is a valuable quality assessment 
tool for the evaluation of botanical materials efficiently and cost effectively. HPTLC 
method offers high degree of selectivity, sensitivity and rapidity combined with single-
step sample preparation. In addition it is a reliable method for the quantitation of nano 
grams level of samples. Thus this method can be conveniently adopted for routine quality 
control analysis. It provides chromatographic fingerprint of phytochemicals which is 
suitable for confirming the identity and purity of medicinal plant raw materials.  
 
Chromatogram Development 
It was carried out in CAMAG Twin Trough chambers. Sample elution was carried 
out according to the adsorption capability of the component to be analysed. After elution, 
plates were taken out of the chamber and dried. 
 
Scanning 
Plates were scanned under UV at 366nm. The data obtained from scanning were 
brought into integration through CAMAG software. Chromatographic finger print was 
developed for the detection of phytoconstituents present in each extract and Rf values 
were tabulated. 
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PHYTOCHEMICAL ANALYSIS 
Test for alkaloids: 
 Mayer's Test: To the test sample, 2ml of mayer's reagent was added, a dull white 
precipitate revealed the presence of alkaloids. 
Test for coumarins:  
 To the test sample, 1 ml of 10% sodium hydroxide was added. The presence of 
coumarins is indicated by the formation of yellow color. 
Test for saponins:  
 To the test sample, 5 ml of water was added and the tube was shaken vigorously. 
Copious lather formation indicates the presence of Saponins. 
Test for tannins:  
  To the test sample, ferric chloride was added, formation of a dark blue or 
greenish black color showed the presence of tannins. 
Test for glycosides- Borntrager’s Test 
 Test drug is hydrolysed with concentrated hydrochloric acid for 2 hours on a 
water bath, filtered and the hydrolysate is subjected to the following tests. To 2 ml of 
filtered hydrolysate, 3 ml of choloroform is added and shaken, choloroform layer is 
separated and 10% ammomia solution is added to it. Pink colour indicates presence of 
glycosides. 
Test for flavonoids: 
 To the test sample about 5 ml of dilute ammonia solution were been added 
followed by addition of few drops of conc. Sulfuric acid. Appearance of yellow color 
indicates the presence of Flavonoids. 
Test for phenols: 
 Lead acetate test: To the test sample; 3 ml of 10% lead acetate solution was 
added.  A bulky white precipitate indicated the presence of phenolic compounds. 
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Test for steroids: 
 To the test sample, 2ml of chloroform was added with few drops of conc. 
Sulphuric acid (3ml), and shaken well. The upper layer in the test tube was turns into red 
and sulphuric acid layer showed yellow with green fluorescence. It showed the presence 
of steroids. 
Triterpenoids 
 Liebermann–Burchard test: To the chloroform solution, few drops of acetic 
anhydride was added then mixed well. 1 ml concentrated sulphuric acid was added from 
the sides of the test tube, appearance of red ring indicates the presence of triterpenoids. 
Test for Cyanins 
A. Aanthocyanin: 
 To the test sample, 1 ml of 2N sodium hydroxide was added and heated for 5 
min at 100ᵒC. Formation of bluish green colour indicates the presence of anthocyanin. 
Test for Carbohydrates - Benedict’s test 
 To the test sample about 0.5 ml of Benedic’s reagent is added. The mixture is 
heated on a boiling water bath for 2 minutes. A characteristic coloured precipitate 
indicates the presence of sugar. 
Proteins (Biuret Test) 
 To extracts 1% solution of copper sulphate was added followed by 5% solution 
of sodium hydroxide, formation of violet purple colour indicates the presence of proteins. 
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STERILITY TEST BY POUR PLATE METHOD: 
Objective  
The pour plate techniques were adopted to determine the sterility of the product. 
Contaminated / un sterile sample (formulation) when come in contact with the nutrition 
rich medium it promotes the growth of the organism and after stipulated period of 
incubation the growth of the organism was identified by characteristic pattern of colonies. 
The colonies are referred to as Colony Forming Units (CFUs).   
Methodology 
Test sample was admixed with sterile distilled water and the mixture were been 
used for the sterility evaluation. About 1ml of the test sample was inoculated in sterile 
petri dish to which about 15 mL of molten agar 45
o
C were added. Agar and sample were 
mixed thoroughly by tilting and swirling the dish. Agar was allowed to completely gel 
without disturbing it. (about 10 minutes). Plates were then inverted and incubated at 37
o
 
C for 24-48 hours. Grown colonies of organism was then counted and calculated for 
CFU.  
    
Observation 
No growth was observed after incubation period. Reveals the absence of specific 
pathogen 
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TOXICOLOGICAL STUDY 
ACUTE ORAL TOXICITY STUDY OF POORANATHI CHOORANAM  
(OECD GUIDELINE – 423) 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals of 
a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on average 
2-4 steps may be necessary to allow judgement on the acute toxicity of the test 
substance.  
 This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed doses, 
adequately separated to enable a substance to be ranked for classification 
purposes and hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least two 
doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with 
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency and 
repeatability.  
Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of a 
minimum number of animals per step, sufficient information is obtained on the acute 
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toxicity of the test substance to enable its classification. The substance is administered 
orally to a group of experimental animals at one of the defined doses. The substance is 
tested using a stepwise procedure, each step using three animals of a single sex. Absence 
or presence of compound-related mortality of the animals dosed at one step will 
determine the next step, i.e. 
− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance to 
one of a series of toxicity classes. 
Methodology: 
Selection of Animal Species  
The preferred rodent species is the wistar albino rat, although other rodent species 
may be used. Healthy young adult animals are commonly used laboratory strains should 
be employed. Females should be nulliparous and non-pregnant. Each animal, at the 
commencement of its dosing, should be between 6 to 8 weeks old and the weight (150-
200gm) should fall in an interval within±20 % of the mean weight of any previously 
dosed animals.  
Housing and Feeding Conditions 
The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be artificial, 
the sequence being 12 hours light, 12 hours dark. For  feeding,  conventional  laboratory  
diets may be used with an unlimited supply of drinking water. Animals may be group-
caged by dose, but the number of animals per cage must not interfere with clear 
observations of each animal. 
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Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, 
and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to 
the laboratory conditions 
Test Animals and Test Conditions:  
Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
kings institute, Chennai. All the animals were kept under standard environmental 
condition (22±3°C).  The animals had free access to water and standard pellet diet 
(Saimeera foods, Bangalore). 
Preparation of animals:  The animals are randomly selected, marked to permit 
individual identification, and kept in their cages for at least 7 days prior to dosing to 
allow for acclimatization to the laboratory conditions 
Preparation for Acute Toxicity Studies 
Rats were deprived of food overnight (but not water 16-18 h) prior to 
administration of the, POORANATHI CHOORANAM  
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
IAEC No: LV/04/CLBMCP/2018 
Test Substance  : POORANATHI CHOORANAM  
Animal Source  : Kings institute, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : >6 weeks 
Body Weight on Day 0 :180-300 gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
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Identification of animals : By cage number, animal number and individual    
    marking by using Picric acid. 
Numberofanimals  : 3 Female/group,  
Route of administration :   Oral  
Diet    : Pellet feed supplied by Saimeera foods Pvt Ltd, Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages   
      provided with bedding of husk. 
Housing temperature : between 22ºC +3ºC.  
Relative humidity  : between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
Administration of Doses:  
POORANATHI CHOORANAM  was suspended in water and administered to the 
groups of wistar albino rats in a single oral dose by gavage using a feeding needle. The 
control group received an equal volume of the vehicle. Animals were fasted 12 hours 
prior to dosing. Following the period of fasting, the animals were weighed and then the 
test substance was administered. Three Female animals are used for each group. The dose 
level of 5, 50, 250 and 500 mg/kg body weight was administered stepwise. After the 
substance has been administered, food was withheld for a further 3-4 hours. The principle 
of laboratory animal care was followed. Observations were made and recorded 
systematically and continuously as per the guideline after substance administration. The 
visual observations included skin changes, mobility, aggressively, sensitivity to sound 
and pain, as well as respiratory movements. Finally, the number of survivors was noted 
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after 24 hrs and these animals were then monitered for a further 14 days and observations 
made daily. The toxicological effect was assessed on the basis of mortality. 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of recovery 
period, and may thus be extended when considered necessary. The times at which signs 
of toxicity appear and disappear are important, especially if there is a tendency for toxic 
signs to be delayed. All observations are systematically recorded with individual records 
being maintained for each animal. 
Observations include changes in skin and fur, eyes and mucous membranes, and 
also respiratory, circulatory, autonomic and central nervous systems, and somatomotor 
activity and behavior pattern. Attention was directed to observations of tremors, 
convulsions, salivation, diarrhea, lethargy, sleep and coma. The principles and criteria 
summarized in the Humane Endpoints Guidance Document taken into consideration. 
Animals found in a moribund condition and animals showing severe pain or enduring 
signs of severe distress was humanly killed. When animals are killed for human reasons 
or found dead, the time of death was recorded. 
REPEATED DOSE 28-DAY ORAL TOXICITY STUDY OF 
POORANATHI CHOORANAM 
Test Substance  : POORANATHI CHOORANAM  
Animal Source  : Kings institute, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : >6 weeks 
Body Weight    :180-300 gm. 
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Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals :By cage number, animal number   and    individual  
    marking by using Picric acid 
Diet    : Pellet feed supplied by Saimeera foods Pvt Ltd,        
      Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages   
       provided with bedding of husk. 
Housing temperature : between 22ºC +3ºC.  
Relative humidity  : between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
TABLE: 
 
 
Groups No of Rats 
Group I  Vehicle control  12(6male,6 female) 
Group II  POORANATHI CHOORANAM  50mg/kg 12 (6male,6 female) 
Group III POORANATHI CHOORANAM250mg/kg 12 (6male,6female) 
Group IV POORANATHI CHOORANAM500mg/kg 12(6male,6female) 
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Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. 
Each group consist of 12 animals (Male -6, and Female-6). First group treated as a 
control and other three group were treated with test drug (low, mid, high) for 28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior to 
the initiation of treatment. Each animal was marked with picric acid. The females were 
nulliparous and non-pregnant. 
Justification for Dose Selection: 
As per OECD guideline three dose levels were selected for the study. They are 
low dose (50 mg/kg), mid dose dose (250 mg/kg), high dose (500 mg/kg). X is calculated 
by multiplying the therapeutic dose of human (3000mg/kg) and the body surface area of 
the rat (0.018). i.e X dose is 50 mg/kg/animal, 5X mid dose is 250 mg/kg, 10 X high dose 
is 500 mg/kg. 
Preparation and Administration of Dose: 
POORANATHI CHOORANAM  is suspended with water, It was administered to 
animals at the dose levels of 50, 250 and 500 mg/kg. The test substance suspensions were  
freshly prepared every two days once for 28 days. The control animals were 
administered vehicle only. The drug was administered orally by using oral gavage once 
daily for 28 consecutive days. 
Observations: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the 
course of study. 
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Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the 
treated dose groups.  
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of  study. 
Necropsy: 
All the animals were sacrificed by excessive anesthesia on day 29. Necropsy of all 
animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals fasted 
over-night. Blood samples were collected from orbital sinus using sodium heparin 
(200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for Hematology as 
anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 minutes. 
Hematological Investigations: 
Hematological parameters were determined using Haematology analyzer.  
Biochemical Investigations:  
Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group than 
the low, then the mid dose group will also be examined. Organs will be collected from all 
animals and preserved in 10% buffered neutral formalin for 24 h and washed in running 
water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in an auto 
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technicon and then cleared in benzene to remove absolute alcohol. Embedding was done 
by passing the cleared samples through three cups containing molten paraffin at 50°C and 
then in a cubical block of paraffin made by the “L” moulds. It was followed by 
microtome and the slides were stained with Haematoxylin-eosin red. 
Statistical analysis:  
Findings such as body weight changes, water and food consumption, hematology 
and blood chemistry were subjected to One-way ANOVA followed by dunett test using a 
computer software programme – Graph pad  version 5.0 .All data were summarized in 
tabular form, (Table-6 to 12) 
PHARMACOLOGICAL STUDY: 
ANTI-INFLAMMATORY STUDIES USING POORANATHI CHOORANAM 
(PCM) 
For the experiment, the animals were divided into 5 groups with 6 animals in each group. 
 Group-I (control) received 3% gum acacia 10 ml/kg p.o. 
 Group-II (Carageenan) received 0.1ml of 1% w/v suspension of carrageenan S.C 
 Group-III (standard) received Indomethacin 40 mg/kg p.o. 
 Group-IV(Test-1) received PCM 100mg/kg p.o. 
 Group-V(Test-2) received PCM 200mg/kg p.o. 
All the drugs were administered orally and the volume of medicaments kept 
constant at 10 ml/kg body weight of the animals it was administered orally to rats 1 hr 
before subcutaneous injection of carrageenan. After 1 hr 0.1ml of 1% w/v suspension of 
carrageenan was injected into sub-plantar region of the left hind paw to all the groups. 
The paw volume was measured at 1, 2, 3, 4, and 5 hr using plethysmometer (Model 7150 
UGO Basile, Italy) Edema was expressed as the mean increase in paw volume relative to 
control animals.  
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ANALGESIC ACTIVITY 
Eddy’s Hot Plate Test 
The hot plate test Eddy and Leimbach (1953) is a simple behavioral screen used 
for estimating the effects of analgesics on the threshold for detecting pain. It is based on 
the principle that when rodents are placed onto a hot surface they will initially 
demonstrate the aversive effects of the thermal stimulus by licking their paws and, 
ultimately, by overt attempts to escape the environment (jumping). Substances that alter 
nociceptive threshold either increase the latency to licking/jumping (analgesic effect)  
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5. RESULTS AND OBSERVATIONS 
 
ORGANOLEPTIC CHARACTERS: 
Table –5.1: Organoleptic character of PC 
STATE Solid 
APPEARANCE Pale Greenish 
NATURE Fine powder 
ODOR  Characteristic odor 
FLOW PROPERTY Dry Free flowing 
 
PHYSICOCHEMICAL EVALUATION: 
Table – 5.2: Physicochemical evaluation of PC 
S.No Parameter Mean (n=3) SD 
1.  Loss on Drying at 105 °C (%) 2.133 ± 0.12 
2.  Total Ash (%)  8.61  ±  0.87 
3.  Acid insoluble Ash (%) 0.29  ± 0.07 
4.  Alcohol Soluble Extractive (%) 13.07 ± 0.65 
5.  Water soluble Extractive (%) 16.57 ± 1.745 
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HEAVY METAL ANALYSIS BY AAS 
Table –5.3: Heavy Metal Analysis of PC  
Name of the Heavy 
Metal 
Absorption Max 
Λ max 
Result Analysis Maximum Limit 
Mercury 253.7 nm BDL 1 ppm 
Lead 217.0 nm 0.18 10 ppm 
Arsenic 193.7 nm 0.05 3 ppm 
Cadmium 228.8 nm 0.44 0.3 ppm 
BDL- Below Detection Limit 
Report and Inference 
• Results of the present investigation have clearly shows that the sample has no 
traces of Mercury.  Further the results show the presence of Lead, Arsenic and 
cadmium at 0.18, 0.05 and 0.44 ppm level. 
• The reported heavy metal seems very low when compare to the allowed 
recommendedlimit. 
TLC AND HPTLC ANALYSIS 
 TLC Analysis at 366 nm 
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Track at All Wavelength 
 
HPTLC finger printing of Sample PC 
  
   
Peak Table 
Table5.4 
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REPORT 
HPTLC finger printing analysis of the sample PC reveals the presence of four prominent 
peakscorresponds to presence of four versatile phytocomponents present with in it. Rf value 
of the peaks rangesfrom 0.17 to 0.88. Further the peak 2 and 3 occupies the major 
percentage of area of 36.26 and 45.11 %which denotes the abundant existence of such 
compound. Followed by this peak 1 and 4 occupies thepercentage area of 9.16 and 9.47 %.
  
PHYTOCHEMICAL ANALYSIS 
RESULT 
Table 5.5 Phytochemical analysis of PC 
S.NO TEST OBSERVATION 
1 Alkaloids - 
2 Flavanoids + 
3 Glycosides + 
4 Steroids + 
5 Triterpenoids - 
6 Coumarin - 
7 Phenols + 
8 Tanin + 
9 Protein - 
10 Saponins + 
11 Sugar + 
12 Anthocyanin - 
13 Betacyanin - 
+ indicates Presence and - indicates Absence of the Phytocomponents 
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TESTS DONE FOR: 
Test for Alkaloids, Flavonoids, Glycosides, Steroids and Triterpenoids 
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Test for Coumarins, Phenol, Tanins, Saponin, Proteins 
 
Test for AnthoCyanin and Carbohydrates 
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STERILITY TEST BY POUR PLATE METHOD 
  
 
Observation 
No growth was observed after incubation period. Reveals the absence of 
specific pathogen 
Result 
No growth / colonies were observed in any of the plates inoculates with the 
test sample 
Table 5.6  STERILITY TEST BY POUR PLATE METHOD 
Test Result Specification As per 
AYUSH/WHO 
Total Bacterial Count Absent NMT 105CFU/g As per AYUSH 
specification 
Total Fungal Count Absent NMT 103CFU/g 
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TOXICOLOGICAL STUDY 
Acute oral toxicity study of POORANATHI CHOORANAM  
Observation done: 
Table 5.7   Dose finding experiment and its behavioral Signs of acute oral Toxicity 
SL              Group 
           CONTROL 
Observation SL Group TEST 
GROUP 
Observation 
1 Body weight Normal 1 Body weight Normally increased 
 2 Assessments of posture Normal 2 Assessments of 
posture 
Normal 
3 Signs of Convulsion Limb 
paralysis 
Normal 3 Signs of 
Convulsion 
  
Absence of sign (-) 
4 Body tone Normal 4 Body tone Normal 
5 Lacrimation Normal 5 Lacrimation Absence 
6 Salivation Normal 6 Salivation Absence 
7 Change in skin color No significant 
color change 
7 Change in skin 
color 
No significant color 
change 
8 Piloerection Normal 8 Piloerection Normal 
9 Defecation Normal 
 
9 Defecation Normal 
 10 Sensitivity response Normal 10 Sensitivity 
response 
Normal 
11 Locomotion Normal 11 Locomotion Normal 
12 Muscle gripness Normal 12 Muscle 
gripness 
Normal 
13 Rearing Mild 13 Rearing Mild 
14 Urination Normal 14 Urination Normal 
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Behaviour: 
 The animals will be observed closely for behaviour in the first four 
hours which  includes abnormal gait, aggressiveness, exophthalmos, ptosis, 
akinesia, catalepsy, convolusion, excitation, head twitches, lacrimation, loss 
of corneal reflex, loss of traction, piloerection  reactivity of touch, salivation, 
scratching, sedation, chewing,  head movements, sniffing, straub, tremor and 
writhes, diarrhea, leathery, sleep and coma. 
Body Weight:  
Individual weight of animals was determined before the test substance 
was administered and weights will be recorded at day 1, 7, and 14 of the 
study. Weight changes were calculated and recorded. At the end of the test, 
surviving animals were weighed and humanly killed. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the 
treated dose groups.  
Mortality: 
Animals were observed for mortality throughout the entire period. 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for 
each test group the number of animals used, the number of animals 
displaying signs of toxicity, the number of animals found dead during the 
test, description of toxic symptoms,, weight changes, food and water intake. 
No of animals in each group:3 
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Table 5.8 (Observational study Results) 
 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
 
500 
mg/kg 
 
+ - - + - + - - - - - - - - - - - - - - 
 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8.Tremors 9.Convulsions 10. Muscle Spasm 11. 
Catatonia 12. Muscle relaxant 13. Hypnosis 14.Analgesia 15.Lacrimation 
16.Exophthalmos 17.Diarrhea 18.Writhing 19.Respiration 20.Mortality. 
 
(+  Present, -  Absent) 
Table 5.9( Body weight Observation) 
 
 
     
Table 5.10Water intake (ml/day) of Wistar albino rats group exposed to 
(POORANATHI CHOORANAM ): 
 
 
 
 
 
 
N.S- Not Significant,**(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
DOSE 
 
DAYS 
1 7 14 
CONTROL 186.6± 2.75 189.2± 3.87 194.2 ± 7.62 
500 mg/kg 182.5± 4.08 184.2± 2.16 187.4 ± 2.67 
P value (p)* NS NS NS 
DOSE 
 
DAYS 
1 6 14 
CONTROL 28.5 ± 2.74 30.0± 9.13 32.4± 3.13 
500 mg/kg 30.4±2.33 36.6±1.11 38.9± 2.19 
P value (p)* NS NS NS 
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Table 5.11: Food intake (gm/day) of Wistar albino rats group exposed to 
POORANATHI CHOORANAM  
 
DOSE 
 
DAYS 
1 7 14 
CONTROL 23.56±3.36 28.60±2.42 31.61±5.46 
500 mg/kg 22.42±1.64 29.31±1.22 32.22±3.24 
P value (p)* NS NS NS 
 
SUB ACUTE TOXICITY 
Repeated Dose 28- day oral toxic study of POORANATHI 
CHOORANAM  
 
Table 5.12: Body weight of wistar albino rats group exposed to PCM 
 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
 
 
 
 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 165.6±  2.76 166.4 ± 3.42 167.7 ± 3.26 169.2 ± 3.73 170.7 ± 1.31 
LOW DOSE 160.2 ± 2.12 162.7 ± 3.64 164.4± 1.51 165.2 ± 1.66 166.42± 2.76 
MID DOSE 166.6± 1.64 167.3 ± 2.74 159.4 ± 8.12 162.1 ± 3.36 163.7 ± 3.11 
HIGH DOSE 167.4± 6.74 169.6 ± 3.72 162.6 ± 2.46 167 ± 6.81 161.92 ± 2.49 
P value (p)* NS NS NS NS NS 
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Table 5.13: Water intake (ml/day) of Wistar albino rats group exposed to PCM 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 31.5 ± 8.95 32.0 ±6.23 28.5±6.23 29.12±8.19 31.5±3.96 
LOW DOSE 21.5±3.28 21.4±3.22 21.7±3.02 21.2±3.29 24.9±3.11 
MID DOSE 26.7±4.33 26.3±2.11 27.1±2.43 28.4±2.11 32.4±2.34 
HIGH DOSE 20.1±1.32 20.2±2.13 22.7±2.13 25.2±1.73 28.4±2.65 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01),  *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
 
Table 5.14:Food intake (gm/day) of Wistar albino rats group exposed to PCM 
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 37.12 ±5.37 38.5±3.22 39.5±3.37 38.5±3.37 37.12±3.12 
LOW DOSE 43.7±2.68 44.3±1.12 44.1±1.18 44.4±2.12 44.6±2.42 
MID DOSE 46.2±3.75 45.2±3.60 45.2±4.25 45.4±2.68 47.2±2.44 
HIGH DOSE 47.2±2.34 47.2±2.64 48.6±2.66 49.2±3.20 49.0±3.62 
P value (p)* NS NS NS NS NS 
 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test 
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Table 5.15: Haematological parameters of Wistar albino rats group exposed to PCM 
 
Category Control Low dose Mid dose High dose P value 
(p)* 
Haemoglobin(g/dl) 14.8±1.88 13.88±1.66 14.94±0.66 15.28±0.96 N.S 
Total WBC (×103   
l) 
10.91±2.59 11.25±3.73 11.48±3.91 12.20±3.17 N.S 
Neutrophils(%) 32.65±1.06 33.23±2.14 35.61±1.36 35.40±2.20 N.S 
lymphocyte (%) 69.34±2.48 72.12±3.12 72.48±2.66 73.10±3.16 N.S 
Monocyte (%) 0.78±0.17 0.79±0.09 0.82±0.03 0.84±0.06 N.S 
Eosinohil(%) 0.64±0.09 0.68±0.02 0.70±0.06 0.72±0.04 N.S 
Platelets cells103/µl 687.17±8.76 702.71±8.16 725.18±9.0 726.16±9.74 N.S 
Total RBC 106/µl 7.99±0.12 7.82±0.57 8.82±0.59 8.38±0.72 N.S 
PCV% 37.79±0.6 43.35±1.13 45.2±1.68 46.82±2.54 N.S 
MCHC g/dL 33.6±2.23 35.09±1.29 35.98±1.22 36.03±1.24 N.S 
MCV fL(µm3) 49.17±3.64 50.20±1.22 52.28±1.24 53.24±1.44 N.S 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
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Table 5.16 :Biochemical Parameters of Wistar albino rats group exposed to PCM 
BIOCHEMICAL 
PARAMETERS 
CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
GLUCOSE (R) (mg/dl) 76.45±13.4 78.16±8.44 78.26±11.20 78.42±11.6 N.S 
T.CHOLOSTEROL(mg/dl) 115.26±1.83 115.45±1.83 116.42±1.78 116.22±1.73 N.S 
TRIGLY(mg/dl) 46.35±1.48 46.32±1.48 44.58±1.30 45.66±1.33* N.S 
LDL 72.81±2.13 71.24±2.14 72.8±2.14 71.64±4.32 NS 
VLDL 15.2±2.44 15.42±4.64 15.44±6.64 15.64±4.36 NS 
HDL 26.66±6.88 26.86±2.24 26.68±4.66 31.78±2.22 NS 
Ratio 
1(T.CHO/HDL) 
4.42±2.44 4.16±3.14 4.34±8.44 4.46±2.22 NS 
Ratio 2(LDL/HDL) 
 
2.83±4.22 2.84±2.22 2.86±2.20 2.96±6.02 NS 
Albumin(g/dL) 3.63±0.17 3.43±0.12 3.14±2.02 
3.24±6.86 
NS 
  
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table 5.17: Renal function test of ofWistar albino rats group exposed to PCM 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 13.35±0.99 14.31±0.16 13.06±1.08 13.48±1.12 N.S 
CREATININE(mg/dl) 0.28±0.08 0.36±0.06 0.52±0.04 0.66±0.02 N.S 
BUN(mg/dL) 15.02±0.10 16.10±0.60 16.22±0.44 18.10±2.12 NS 
URIC ACID(mg/dl) 5.17±0.35 5.31±0.43 5.72±1.25* 5.58±0.23 S 
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 NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Table 5.18: Liver Function Test of ofWistar albino rats group exposed to PCM 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)*  
T BILIRUBIN(mg/dl). 0.48±0.07 0.53±0.06 0.51±0.08 0.48±0.05 N.S 
SGOT/AST(U/L) 79.95±1.39 78.35±0.51 76.01±1.53 81.55±1.03 N.S 
SGPT/ALT(U/L) 31.23±1.28 30.91±1.59 28.34±1.48 34.32±0.68 N.S 
ALP(U/L) 143.25±8.70 142±16.17 147.16±24.07* 149.33±14.65* S 
T.PROTEIN(g/dL) 5.32±0.38 6.48±0.34 7.01±0.23 7.53±0.46 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One way 
ANOVA followed by Dunnett’s test) 
HISTO PATHOLOGY 
CONTROL GROUP 
Kidney    Liver     Spleen 
       
TEST GROUP (HIGH DOSE) 
Kidney    Liver     Spleen 
         
 
RESULTS AND OBSERVATIONS 
109 
 
PHARMACOLOGICAL STUDY: 
ANTI-INFLAMMATORY STUDIES USING POORANATHI CHOORANAM 
(PCM) 
 
Table: 5.19 PAW EDEMA VOLUME 
Group Dose Initial paw 
volume 
Change in paw edema mm at different time intervals 
  0hr 1 hr 2hr 3hr 4hr 5hr 
I Control 1.20 ± 0.14 1.20±0.14 1.20±0.14 1.20±0.14 1.20±.14 1.20±0.14 
II Carrageenan 1.21± 0.17 
1.91 ± 0.21 2.27 ± 0.02 2.37 ± 0.14 2.48 ± 0.18 
2.62 ± 
0.17** 
III Indomethacin 1.01± 0.06 
2.10 ± 0.26 1.56 ± 0.15 
1.47 ± 0.05 
 
1.34 ± 0.18 
1.15 ± 
0.16** 
 
IV Low dose 1.34 ± 0.11 1.46 ± 0.32 1.52 ± 0.18 1.64 ± 0.22 
 
1.53 ± 0.22 1.58 ± 
0.24** 
V High dose  1.24±0.42 1.98 ± 0.22 1.82 ± 0.23 
 
1.66 ± 0.44 1.62 ± 0.18 
 
1.20 ± 
0.12** 
The paw volume up to the tribiotural articulation was measured at 0, 1, 2, 3, 4, 5 hrs 
 
Table: 5.20 
Group Initial paw 
volume 
5 hr in mm Difference in paw 
volume 
Percentage protection  
I 1.20 ± 0.14 1.20±0.14 0.00 100 
II 1.21± 0.17 2.82 ± 0.17 1.61 15.62 
III 1.01± 0.06 1.15 ± 0.16 
 
0.14 96.68 
IV 1.44 ± 0.13 1.69 ± 0.32 0.25 41.42 
 1.32 ±0.44 1.46 ± 0.12 0.14 75.45 
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Percentage protection is calculated by the formulae:  (T2---T1/T2 )  x 100 
T 1----normal control 
T2 ----drug treated test  
   Chart 5.1Percentage protection of PC in inflammation 
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ANALGESIC ACTIVITY 
Eddy’s Hot Plate Test 
Table 5.21 Effect of Pooranathichooranam on Eddys hot plate method 
Group  Dose  Pretreatment  Reaction time in seconds 
   0.5 hr 1hr  2hr 4hr 
Control   3.7±0.20 3.3±0.30 4.2±0.22 4.4±0.34 4.0±0.48 
Pentazocine  3.9±0.26 6.4±0.27 7.1±0.62* 7.6±0.26* 7.1±0.36* 
Test drug 200mg 3.5±0.32 6.2±0.28 6.9±0.54* 7.1±0.36* 6.8±0.29 
Test drug 400mg 3.8±0.42 6.8±0.56 7.4±0.46* 7.8±0.40* 7.1±0.32 
 
One way ANOVA followed by Dunnetts test, Values are Mean ± SEM, n=6 
P<0.05* 
Chart 5.2:  Effect of Pooranathichooranam on Eddys hot plate method 
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Results of the study were observed with respect to the following criteria 
1. Age distribution 
2. Gender distribution  
3. Occupational distribution  
4. Socio-economic status 
5. Diet  
6. Duration of illness 
7. Paruvakalangal 
8. Thinaigal. 
9. ParuvaKaalam (Season)  
10. Disturbances in Vali 
11. Disturbances in Azhal 
12. Disturbances in Iyyam 
13. Envagaithervugal 
14.  Neikkuri 
15.  Naadi 
16.  Clinical Prognosis 
 Group I 
 Group II 
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AGE DISTRIBUTION 
Table: 5.22Age Distribution 
S.No Age  No of cases Percentage 
1 20-30 4 10% 
2 31-40 14 35% 
3 41-50 16 40% 
4 51-60 6 15% 
 
Chart 5.3: Age Distribution 
 
INFERENCE: 
Among 40 cases, 10% of cases were in the 20-30 age group. 35%, 40 % and 15% of 
cases were in the age of 31-40, 41-50 and 51-60 respectively 
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GENDER 
TABLE 5.23: Gender 
S.No Gender No of Cases Percentage 
1. Male 13 32.5 % 
2. Female 27 67.5 % 
 
    Chart 5.4: Gender 
  
INFERENCE: 
 Among 40 cases, 13% of cases were Males and 67.5% of patients were females.  
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OCCUPATIONAL DISTRIBUTION 
  Table 5.24: Occupational Distribution 
Occupation No of cases Percentage 
Coolie 3 7.5% 
Driver 2 5% 
Electrician 1 2.5% 
House wife 18 45% 
IT Employee 3 7.5% 
Painter 2 5% 
Salesman 2 5% 
Tailor 4 10% 
Teacher 5 12.5% 
 
   Chart 5.5: Occupational Distribution  
INFERENCE: 
Among 40 cases, 45% of cases were House wives, 12.5% of cases were Teachers, 10% 
were Tailor, 7.5% of cases were IT employees And Coolies. Painters, Salesmans & 
Drivers were 5% each. Electricians were 2.5% each. 
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SOCIO ECONOMIC STATUS 
Table 5.25: Socio Economic Status 
Socio economic status No of Patients Percentage 
Lower 8 20% 
Upper lower 14 35% 
Lower middle 13 32.5% 
Upper middle 4 10% 
Upper 1 2.5% 
 
 
Chart 5.6: Socio Economic Statu 
 
 
INFERENCE: 
Among 40 cases, 20% of cases were Lower, 35% of cases were upper lower, 32.5% were 
Lower middle, 10% of cases were Upper middle And 2.5% cases were Upper group. 
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DISTRIBUTION OF DIET 
Table 5.26: Distribution Of Diet 
Diet No of Patients Percentage 
Vegetarian 8 20% 
Mixed Diet 32 80% 
 
Chart 5.7: Distribution Of Diet 
 
 
 
 
 
INFERENCE 
Among 40 cases, 80% of cases were consuming mixed diet and 20% were 
Vegetarian 
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DURATION OF ILLNESS 
 
Table 5.27: Duration Of Illness 
Duration of illness No of Patients Percentage 
Below 1 month 1 25% 
1-3 months 8 20% 
4-6 months 10 25% 
7 month – 12 months 17 42.5% 
13 months – 24 months 2 5% 
25 months – 36 months 2 5% 
 
Chart 5.8: Duration Of Illness 
  
 
INFERENCE: 
Out of 40 patients subjected in the present study, 25% belonged to less than 1 
month of illness and others were 20% in 1-3 months, 25% in 4-6 months, 42.5% in 7 
months-12 month, 5% in13-24 months and 25-36 months of illness. 
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DISTRIBUTION AMONG PARUVAKAALANGAL 
 
Table 5.28: Distribution Among Paruvakaalangal 
S.No  Paruvakaalam  No of cases Percentage 
1. Kaarkaalam 5 12.5% 
2. Koothirkaalam 8 20% 
3. Munpanikaalam 0 0% 
4. Pinpanikaalam 1 2.5% 
5. Ilavenilkaalam 12 30% 
6. Muthuvenilkaalam 14 35% 
 
Chart 
5.9: 
Distribution 
AmongParuvak
aalangal 
 
 
 
 
 
 
 
INFERENCE: 
 Among 40 patients,  12.5%, 20%, 2.5% , 30% and 35%  of patients came in Kaar, 
koothir, Pinpani, Ilavenil and Muthuvenilkaalam. No cases were came in 
Munpanikaalam. 
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DISTRIBUTION AMONG THINAI 
 
Table 5.29: Distribution Among Thinai 
S.No Thinai No of Patients Percentage 
1 Kurinji 2 5% 
2 Mullai 0 0 
3 Marutham 2 5% 
4 Neithal 36 90% 
5 Paalai 0 0 
 
Chart 5.10: Distribution Among Thinai 
 
 
INFERENCE: 
 Out of 40 patients, 90% of patients belongs to Neithal Nilam and 5% of patients 
belong to Marutha & Kurinji Nilam 
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DISTRIBUTION AMONG KAALAM 
 
Table 5.30: Distribution Among Kaalam 
S.No Kaalam No of patients Percentage 
1 Vatham 6 15% 
2 Pitham 34 85% 
3 Kabam 0 0 
 
 
Chart 5.11: Distribution AmongKaalam 
 
 
INFERENCE: 
 Out of 40 patients, 15% of patients were belonged Vathakaalam and 85% 
belonged to Pithakaalam 
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DISTRIBUTION OF VATHAM 
Table 5.31: Distribution Of Vatham 
Vatham No of Patients Percentage 
Pranan   0 0 
Abanan 18 45% 
Udanan 2 5% 
Vyanan 40 100% 
Samanan 40 100% 
Naagan 0 0 
Koorman 0 0 
Kirukaran 0 0 
Devadhathan 0 0 
Dhananjeyan - -  
 
 Chart 5.12: Distribution Of Vatham 
             
INFERENCE: 
 Out of 40 Patients, Vyanan and Samanan were affected in all the patients. Abanan 
and udanan were affected in 45% and 5% of patients respectively. 
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DISTRIBUTION OF PITHAM 
Table5.32: Distribution Of Pitham 
S.No Pitham No of Patients Percentage 
1 Analagam 9 22.5% 
2 Ranjagam 0 0 
3 Prasagam 0 0 
4 Saathagam 40 100% 
5 Alosagam 0 0 
 
Chart 5.13: Distribution Of Pitham 
 
 
INFERENCE: 
 Out of 40 patients, Anarpitham was affected in 22.5% of patients and 
Saathagapitham was affected in all the patients (100%). 
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DISTRIBUTION OF KABAM 
 
Table 5.33: Distribution Of Kabam 
S.No Kabam No of Patients Percentage 
1 Avalambagam 40 100% 
2 Kilethagam 0 0 
3 Pothagam 0 0 
4 Tharpagam 0 0 
5 Santhigam 40 100% 
 
Chart 5.14: Distribution Of Kabam 
 
 
 
INFERENCE: 
 Out of 40 patients, Avalambakam, Santhigam was affected in all patients (100%).  
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DISTRIBUTION OF ENVAGAI THERVU 
 
Table 5.34: Distribution Of EnvagaiThervu 
S.No Envagaithervu No of Patients Percentage 
1 Nadi 40 100 
2 Sparism 0 0 
3 Naa 3 7.5 
4 Niram 0 0 
5 Mozhi 0 0 
6 Vizhi 0 0 
7 Malam 18 45% 
8 Moothiram 0 0 
 
Chart 5.15: Distribution Of EnvagaiThervu 
 
 
INFERENCE: 
Out of 40 patients, Nadi was affected in100% of patients, Naa was affected in 
7.5% of patients and Malam was affected in45% of patients. 
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NEIKKURI 
Table 5.35: Neikkuri 
S.No Neikkuri No of Cases Percentage 
1 VathaNeer 29 72..5% 
2 PithaNeer 8 20% 
3 KabaNeer 3 7.5% 
 
Chart 5.16: Neikkuri 
 
 
 
 
INFERENCE: 
 Out of 40 patient’s urine sample vathaneer was present in 72.5% of patient’s urine 
sample, Pithaneer was present in 20% of patient’s urine sample and Kabaneer was 
present in 7.5% of urine sample. 
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DISTRIBUTION OF NADI 
 
Table 5.36: Distribution Of Nadi 
S.No Nadi No of cases Percentage 
1 Vathapitham 32 53.4 
2 Pithavatham 18 30 
3 Vatham 10 16.6 
 
 
Chart 5.17: Distribution Of Nadi 
 
 
 
 
INFERENCE: 
 Out of 40 patients, Vathapithanadi, Pithavathanadi and vathanadi were present in 
54.3%, 30% and 16.6% of patients. 
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IMPROVEMENT IN SUBJECTS TREATED WITH INTERNAL MEDICINE 
(GROUP I) 
 
Table: 5.37 Improvement in subjects treated with Internal medicine (Group I) 
S.No Clinical features Before 
Treatment 
After 
Treatment 
Percentage 
of 
Response 
1. Neck pain 20 6 70% 
2. Radiating pain in upper 
limbs 
12 2 83% 
3. Stiffness of neck 5 1 80% 
4. Numbness 7 1 86% 
5. Giddiness 3 1 67% 
6. Tenderness 4 1 75% 
7. Movement restriction 1 1 0% 
8. Overall response 66% 
 
Chart 5.18: Improvement in subjects treated with Internal medicine (Group I) 
 
INFERENCE: 
70% of patients were relieved from Neck pain completely, 83%, of patients were 
relieved from Radiating pain in upper limbs.  80%, 86%, 67%, 75% and 0% of patients 
were relieved from Neck stiffness, Numbness, Numbness, Giddiness, Tenderness and 
Movement restriction respectively. 
RESULTS AND OBSERVATIONS 
129 
 
IMPROVEMENT IN SUBJECTS TREATED WITH INTERNAL, EXTERNAL 
MEDICINE AND OTTRADAM (GROUP 2) 
Table: 5.38 Improvement in subjects treated with Internal, External Medicine and    
Ottradam(Group 2) 
S.No Clinical features Before 
Treatment 
After 
Treatment 
Percentage 
of 
Response 
1. Neck pain 20 1 95% 
2. Radiating pain in upper 
limbs 
10 1 90% 
3. Stiffness of neck 9 1 88% 
4. Numbness 7 0 100% 
5. Giddiness 4 0 100% 
6. Tenderness 3 0 100% 
7. Movement restriction 1 0 100% 
8. Overall response 96% 
 
Chart 5.19: Improvement in subjects treated with Internal, External Medicine and 
Ottradam(Group 2) 
 
INFERENCE: 
100% of patients were relieved from Numbness, Giddiness, Tenderness and 
Movement restriction. 95% of Patients were relieved from Neck Pain. Radiating pain and 
Neck stiffness was relieved for 90 % of patients. 
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CLINICAL PROGNOSIS BASED ON SYMPTOMS (ALL GROUPS) 
Table: 5.39 Clinical prognosis based on Symptoms (All Groups) 
S.No Clinical features Before 
Treatment 
After 
Treatment 
Percentage of 
Response 
1. Neck pain 40 7 82% 
2. Radiating pain in upper 
limbs 
22 3 87% 
3. Stiffness of neck 14 2 85% 
4. Numbness 14 1 93% 
5. Giddiness 7 1 85% 
6. Tenderness 7 1 85% 
7. Movement restriction 2 1 50% 
 
Chart 5.20: Clinical prognosis based on Symptoms (All Groups) 
 
INFERENCE: 
 82% of patients were relieved from Neck pain completely,  87%, of patients were 
relieved from Radiating pain in upper limbs.  85%, 93%, 85%, 85% and 50% of patients 
were relieved fromNeck stiffness, Numbness, Numbness, Giddiness, Tenderness and 
Movement restriction respectively. 
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PAIN ASSESSMENT BASED ON VISUAL ANALOG SCALE –GROUP I 
 Table 5.40: Pain Assessment Based On Visual Analog Scale –Group I  
S.No BT AT Difference Prognosis 
1 6 0 6 Good 
2 8 6 2 Mild 
3 6 0 6 Good 
4 6 0 6 Good 
5 10 8 2 Mild 
6 8 0 8 Good 
7 6 0 6 Good 
8  4 0 4 Moderate 
9 6 0 6 Good 
10 7 5 2 Mild 
11 8 2 6 Good 
12 9 5 4 Moderate 
13 10 7 3 Moderate 
14 8 0 8 Good 
15 6 6 0 No 
16 6 0 6 Good 
17 9 0 9 Good 
18 8 4 4 Moderate 
19 6 0 6 Good 
20 7 0 7 Good 
 
Note: 
Improvement   Change of points in VAS 
Good improvement  : > 5 points 
Moderate improvement : 3-5 points 
Mild improvement  : 1-2 points 
No improvement  : 0 points 
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RESULTS BASED ON VISUAL ANALOG SCALE - GROUP I 
 
Table 5.41: Results Based On Visual Analog Scale - Group I 
Prognosis No of Patients Percentage 
Good Improvement 12 60% 
Moderate Improvement 4 20% 
Mild Improvement 3 15% 
No Improvement 1 5% 
 
 
Chart 5.21: Results Based On Visual Analog Scale - Group I 
 
Inference: 
In Group I, 60% of patients had  Good improvement, 20% of patients had 
moderate  and 15% mild improvement  and 5% of patients had No improvement. 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
Good 
Improvement
Moderate 
Improvement
Mild 
Improvement
No 
Improvement
PROGNOSIS
RESULTS AND OBSERVATIONS 
133 
 
PAIN ASSESSMENT BASED ON VISUAL ANALOG SCALE – GROUP II 
 
Table: 5.42: Pain Assessment Based On Visual Analog Scale – Group II 
S. No BT AT Difference Prognosis 
01 6 0 6 Good 
02 8 0 8 Good 
03 9 0 9 Good 
04 9 0 9 Good 
05 6 0 6 Good 
06 8 0 8 Good 
07 9 0 9 Good 
08 4 0 4 Moderate 
09 6 0 6 Good 
10 8 0 8 Good 
11 10 0 10 Good 
12 8 0 8 Good 
13 9 0 9 Good 
14 7 0 7 Good 
15 6 0 6 Good 
16 9 0 9 Good 
17 8 0 8 Good 
18 6 0 6 Good 
19 9 0 9 Good 
20 6 0 6 Good 
 
Note: 
Improvement   Change of points in VAS 
Good improvement  : > 5 points 
Moderate improvement : 3-5 points 
Mild improvement  : 1-2 points 
No improvement  : 0 points 
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RESULTS BASED ON VISUAL ANALOG SCALE GROUP II 
  
Table 5.43: Pain Assessment Based On Visual Analog Scale – Group II 
Prognosis No of Patients Percentage 
Good Improvement 19 95% 
Moderate Improvement 1 5% 
Mild Improvement 0 0% 
No Improvement 0 0% 
 
 
Chart 5.22: Pain Assessment Based On Visual Analog Scale – Group II 
 
 
Inference: 
 In Group II, 95% of patients had  Good improvement, 5% of patients had 
moderate improvement. None of the patients showed Mild and No improvement. 
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COMPARISION OF  PROGNOSIS OF THREE TREATMENT GROUPS BASED 
ON VISUAL ANALOG SCALE 
Table 5.44: ComparisionOf  Prognosis Of Three Treatment Groups Based On 
Visual Analog Scale 
 
Prognosis Group I Group II 
Good Improvement 60% 95% 
Moderate Improvement 20% 5% 
Mild Improvement 15% 0% 
No Improvement 5% 0% 
 
 
Chart 5.23: ComparisionOf  Prognosis Of Three Treatment Groups Based On 
Visual Analog Scale 
 
INFERENCE: 
On comparing the two treatment groups Group II  had shown better prognosis 
with 95% Good improvement and 5% Moderate improvement than the other treatment 
groups. 
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Table 5.45: Treatment details of Subjective parameters of Group 1: 
 
S.N
O 
OP 
NO/ 
IP NO 
 
Name 
 
Age/ 
Sex 
 
Occupation 
Duration 
of illness 
 Date of 
starting 
treatment 
  Date of 
withdraw
al 
treatment 
 
Results 
01 5262 
 
MUTHUKANI 48/F  
Teacher 
 
2 Months 15.5.2018 27.6.2018 Good 
Improvement 
02 5297 
 
MALLIGA 55/F  
House wife 
36 Years 9.5.2018 1.7.2018 Mild 
Improvement 
 
03 5387 
 
MANNAR MANNAN 46/M  
Painter 
3Months 14.5.2018 6.7.2018 Good 
Improvement 
04 8543 
 
KANNAN 39/M Driver 1 Month 25.5.2018 11.7.2018 Good 
Improvement 
05 9456 
 
RAMADOSS 43/M Salesman 6 Month 29.5.2018 15.7.2018 Mild 
Improvement 
06 9639 
 
HEMANADHAN 50/M Teacher 
 
2 Month 30.5.2018 16.7.2018 Good 
Improvement 
07 9770 
 
CHELLAMMAL 39/F House wife 1 Month 30.5.2018 16.7.2018 Good 
Improvement  
08 3496 
 
SUMATHI 39/F Teacher 
 
5 Month 14.6.2018 31.7.2018 Moderate 
Improvement  
09 3747 
 
PAZHANI RAJ 39/M Coolie 1 Year 15.6.2018 1.8.2018 Good 
Improvement 
10 4323 
 
BILLIAMMA 
 
38/F House wife 9 Months 19.6.2018 6.8.2018 Mild 
Improvement 
11 1185 
/360 
UMA 47/F House wife 7 Months 1.6.2018 16.6.2018 Good 
Improvement   
12 1198 
/795 
SELVAKUMAR 36/M IT 5 Months 4.6.2018 4.7.2018 Moderate 
Improvement  
13 1203 
/886 
GOWRI 48/F House wife 1 Year 4.6.2018 5.7.2018 Moderate 
Improvement 
14 1238 
/1979 
RASAPPA 37/M Painter 9 Months 8.6.2018 23.7.2018 Good 
Improvement 
15 1302 
/4372 
ARUNA 27/F Teacher 
 
2 Years 18.6.2018 7.8.2018 Moderate 
Improvement  
16 1316 
/4776 
BRINDHA 26/F IT 2 Months 19.6.2018 5.8.2018 Good 
Improvement 
17 1462 
/632 
DHANSHERA 40/F IT 6 Months 10.7.2018 19.3.2018 Good 
Improvement   
18 1465 
/2829 
LAKSHMI BAI 53/F House wife 1 Year 12.7.2018 28.8.2018 No  
Improvement 
19 1511 
/2793 
RAMANI 20/F Tailor 1 Year 17.7.2018 23.7.2018 Good 
Improvement 
20 1517 
/2775 
KAMATCHI 50/F House wife 8Months 17.7.2018 26.7.2018 Good 
Improvement 
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Table 5.46: Treatment details of Subjective parameters of Group II: 
S.N
O 
OP 
NO 
/IPNO 
Name Age/ Sex 
Occupatio
n 
Duration 
of illness 
Date of 
starting 
treatment 
Date of 
withdrawal 
treatment 
Results 
01 
 
5947 SAJID IBRAHIM 20/M Electrician 1 Month 23.6.2018 10.8.2018 Good 
Improvement 
02 
 
7710 KOLAVIZHI 32/F Tailor 4 Months 29.6.2018 16.8.2018 Good 
Improvement 
03 
 
9029 MEERA 45/F House wife 6 Months 5.7.2018 18.7.2018 Good 
Improvement 
04 
 
9572 SARATHA 37/F Tailor 5 Months 6.7.2018 19.7.2018 Good 
Improvement 
05 
 
5639 POONKUZHALI 34/F House wife 3 Months 16.7.2018 29.8.2018 Good 
Improvement 
06 
 
6405 THENAVAN 52/F Coolie 4 Months 30.7.2018 12.9.2018 Good 
Improvement 
07 
 
6419 TAMIL SELVI 45/F House wife 9 Months 1.11.2018 18.12.2018 Good 
Improvement 
08 
 
2654 DEEPA 33/F Teacher 1 yesr 20.11.2018 6.1.2018 Moderate 
Improvement 
09 
 
3601 NAGAVALLI 35/F House wife 8 Months 23.11.2018 9.1.2018 Good 
Improvement 
10 
 
8898 KALAIVANI 47/F House wife 10 Months 6.12.2018 22.1.2018 Good 
Improvement 
11 
 
1735 
/961 
KATHAVARAYAN 49/F Coolie 2 Years 17.8.2018 2.9.2018 Good 
Improvement 
12 
 
182 
/4768 
MALLIGA 55/F House wife 1 Year 30.8.2018 12.9.2018 Good 
Improvement 
13 
 
1836 
/5595 
KOMALA DEVI 45/F House wife 1 Year 3.9.2018 22.9.2018 Good 
Improvement 
14 
 
1939 
/460 
AGAMATH ALI 44/M Sales man 3 Months 12.9.2018 28.12.2018 Good 
Improvement 
15 
 
1993 
/2304 
PRABHU 39/M Driver 6 Months 19.9.2018 23.9.2018 Good 
Improvement 
16 
 
2279 
/5876 
AMUDHAVALLI 50/F House wife 8 Months 30.10.2018 17012.2018 Good 
Improvement 
17 
 
2337 
/9287 
JAYANTHI 50/F House wife 2 years 12.11.2018 15.11.2018 Good 
Improvement 
18 
 
2341 
/9396 
BHUVANESWARI 57/F House wife 9 Months 12.11.2018 28.11.2018 Good 
Improvement 
19 
 
2476 
/6035 
VIJAYARANI 54/F House wife 1 Month 29.11.2018 11.12.2018 Good 
Improvement 
20 
 
3093 
/7483 
SASIKUMAR 40/M Tailor 6 Months 26.2.2019 10.5.2019 Good 
Improvement 
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     GROUP I SUBJECT: LAB INVESTIGATION 
 
 
S.NO 
 
 
OP.NO 
& 
IP.NO 
 
 
 
 
       NAME 
 
 
 
 
AGE/SEX 
TC 
(Cells/ 
Cu.mm) 
 
 
DC (%) 
 
 
ESR (mm/ Hr) 
 
Hb 
(gm%) 
 
Blood Sugar 
 
BT 
 
AT 
N B E M L ½ hr 1 hr  
BT 
 
AT 
Random 
(mg/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 5262 
 
MUTHUKANI 48/F 9000 9100 60 62 0 0 3 2 0 0 37 36 26 25 43 40 10.3 10.5 132 124 
2 5297 
 
MALLIGA 55/F 7300 7200 64 60 2 0 5 4 2 1 27 35 16 15 31 30 9.6 10.5 154 167 
3 5387 
 
MANNAR 
MANNAN 
46/M 8900 9600 76 62 0 0 3 3 0 0 21 24 21 17 65 48 10.8 11.2 157 140 
4 8543 
 
KANNAN 39/M 6500 8200 53 68 0 0 7 6 0 0 40 26 7 18 7 16 11.2 11.3 104 98 
5 9456 
 
RAMADOSS 43/M 8800 9800 67 70 0 0 7 3 0 0 26 27 20 39 18 34 9.2 9.3 136 125 
6 9639 
 
HEMANADHAN 50/M 8800 9100 63 61 0 0 6 5 0 0 31 34 5 12 5 10 13.2 13.2 190 170 
7 9770 
 
CHELLAMMAL 39/F 9000 9500 60 67 0 0 5 3 0 0 35 40 8 7 16 15 10.5 11 146 129 
8 3496 
 
SUMATHI 39/F 7700 8000 66 70 0 0 4 3 0    0 30 32 19 15 40 33 10 11 32 160 
9 3747 
 
PAZHANI RAJ 39/M 8500 8900 70 72 0 0 4 2 0 0 28 32 17 33 22 45 13.5 13 132 135 
10 4323 
 
BILLIAMMA 
 
38/F 9200 9600 52 56 0 0 6 4 0 0 42 40 7 8 15 16 12.4 12 145 126 
11 1185 
/360 
UMA 47/F 7000 7300 62 65 0 0 5 2 0 0 28 32 15 12 31 30 11 12 112 100 
12 1198 
/795 
SELVAKUMAR 36/M 8600 8100 61 60 0 0 5 4 4 0 30 36 12 11 27 26 10.4 11 117 98 
13 1203 
/886 
GOWRI 48/F 8300 8500 52 56 1 0 5 4 4 0 40 40 12 11 22 26 12.3 13 140 156 
14 1238 
/1979 
RASAPPA 37/M 9400 9600 65 65 1 0 5 5 3 1 26 29 14 13 33 30   10.3 11 160 167 
15 1302 
/4372 
ARUNA 27/F 6900 6700 50 52 0 0 2 2 0 0 48 46 8 7 16 15 112 12.2 130 110 
16 1316 
/4776 
BRINDHA 26/F 8400 8800 60 54 0 0 2 0 0 0 40 44 6 12 14 24 11.5 12.5 98 104 
17 1462 
/632 
DHANSHERA 40/F 8100 8000 70 65 0 0 5 5 0 0 25 30 14 13 29 26 11.2 11 160 148 
18 1465 
/2829 
LAKSHMI BAI 53/F 7800 8000 67 64 0 0 8 5 0      0 29 31 10 5 17 13 11.8 12.4 127 136 
19 1511 
/2793 
RAMANI 20/F 7600 7900 66 63 0 0 9 7 0 0    20 25 22 19 45 38 10.6 13 159 154 
20 1517 
/2775 
KAMATCHI 50/F 9400 9440 65 64 0 0 7 6 1 0 27 30 25 25 43 40 10.4 11 139 129 
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GROUP II SUBJECT: LAB INVESTIGATION 
 
 
 
S.NO 
 
 
OP.NO 
& 
IP.NO 
 
 
 
 
 
NAME 
 
 
 
 
AGE/SEX 
TC 
(Cells/ Cu.mm) 
 
 
DC (%) 
 
 
ESR (mm/ Hr) 
 
Hb (gm%) 
 
Blood Sugar 
 
BT 
 
AT 
N B E M L ½ hr 1 hr  
BT 
 
AT 
Random(mg/dl) 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 
 
5947 SAJID IBRAHIM 20/M 7700 8200 49 60 1 0 6 5 4 0 40 35 9 10 17 19 10.5 12 160 150 
2 
 
7710 KOLAVIZHI 32/F 7500 8600 50 64 0 0 9 6 0 0 41 30 12 10 20 22 12.5 12.6 126 147 
3 
 
9029 MEERA 45/F 6100 6700 58 63 0 1 4 1     3 1 35 32 30 22 61 46 11.2 12 120 90 
4 
 
9572 SARATHA 37/F 7200 8000 47 55 1 0 7 5 4 2 41 38 12 10 36 25 9.7 10.5 84 82 
5 
 
5639 POONKUZHALI 34/F 9800 10000 71 70 0 0 2 2 5 3 22 25 9 9 24 25 11 11.5 93 104 
6 
 
6405 THENAVAN 52/F 8600 9000 68 59 0 0 7 4 0 2 25 35 10 9 22 18 15 14 104 110 
7 
 
6419 TAMIL SELVI 45/F 8100 8100 55 59 0 1 6 5 3 3 36 32 17 16 23 24 11 12 108 140 
8 
 
2654 DEEPA 33/F 8700 9200 75    71 0 0 8 6 0 1 17 22 18 14 42 37 11.4 13 140 130 
9 
 
3601 NAGAVALLI 35/F 7700 8000 58 59 0 0 7 5 0 0 35 36 8 7 16 13 11.2 11.5 98 94 
10 
 
8898 KALAIVANI 47/F 9250 9500 67 65 0 1 3 3 4 3 26 28 16 15 37 35 12.6 13 95 84 
11 
 
1735 
/961 
KATHAVARAYAN 49/F 9400 9440 65 64 0 0 7 6 1 0 27 30 25 25 43 40 11.4 12 115 116 
12 
 
1826 
/4768 
MALLIGA 55/F 9200 9100 63 59 1 0 7 8 2 0 27 33 7 9 16 18 11 12 100 95 
13 
 
1836 
/5595 
KOMALA DEVI 45/F 9300 9100 65 65 1 0 5 5 3 1 26 29 14 13 33 30 10.3 11 108  120 
14 
 
1939 
/460 
AGAMATH ALI 44/M 7300 7200 64 60 0 0 7 6 1 0 27 30 25 25 43 40 10.4 11 160 152 
15 
 
1993 
/2304 
PRABHU 39/M 6000 6300 55 52 0 0 5 5 0 0 38 40 5 7 25 16 12 13 140 139 
16 
 
2279 
/5876 
AMUDHAVALLI 50/F 8200 8200 58 60 0 0 1 0 0 0 41 40 9 17 18 24 11 11.4 120 135 
17 
 
2337 
/9287 
JAYANTHI 50/F 8600 8900 55 60 0 0 5 4 0 0 15 16 8     15     7 15 9 12 167 147 
18 
 
2341 
/9396 
BHUVANESWARI 57/F 8100 8500 79 73 0 0 2 2 0 0 19 25 10 9 22 22 10.2 11 152 129 
19 
 
2476 
/6035 
VIJAYARANI 54/F 8700 9200 75 71 0 0 8 6 0 1 17 22 18 14 42 37 11.2 13 87 107 
20 
 
3093 
/7483 
SASIKUMAR 40/M 6400 6200 68 68 0 0 5 5 2 1 25 26 30 29 60 54 12 12.5 130 126 
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UP I  SUBJECT : LAB INVESTIGATION 
 
 
S. 
NO 
 
 
 
OP/IP 
NO 
 
 
 
 
NAME 
LIVER  FUNCTION TEST RENAL FUNCTION TEST URINE ANALYSIS 
 
S.Bilurubin 
(mg/dl) 
 
Alkaline 
Phosphatase 
(U/L) 
 
SGOT 
(U/L) 
 
SGPT 
(U/L) 
 
UREA 
(mg/dl) 
 
CREATININE 
(mg/dl) 
 
Albumin 
 
Sugar 
 
Deposits 
BT AT BT AT BT 
 
AT BT 
 
AT BT AT BT AT BT AT BT AT BT AT 
1 5262 
 
MUTHUKANI 0.8 0.6   94 93 20 19 46 47 15 14 0.4 0.3 NIL NIL NIL NIL 1-2 epi 
cells 
1-2 epi 
cells 
2 5297 
 
MALLIGA 0.6 0.2 67 60 23 21 19 16 13 12 0.7 0.7 NIL NIL NIL NIL 2-3- epi 
cells 
1-2 epi 
cells 
3 5387 
 
MANNAR 
MANNAN 
0.2  
     0.1 
77 74 34 32 23 21 9 8 0.8 0.7 NIL NIL NIL NIL 1-2 pus 
cells 
1-2 pus 
cells 
4 8543 
 
KANNAN 0.4 0.2 49 48 12 10 08 09 17 16      1.2 1.1 NIL NIL NIL NIL 2-3- epi 
cells 
1-2 epi 
cells 
5 9456 
 
RAMADOSS 0.3      0.1 80 84 14 14 24 23 13 12 0.7 0.8 NIL NIL NIL NIL 0-1 epi 
cells 
1-2 pus 
cells 
6 9639 
 
HEMANADHAN 0.5 0.4 138 139 24 21 36 36 19 18 0.8 0.8 NIL NIL NIL NIL 1-2 pus 
cells 
1-2 pus 
cells 
7 9770 
 
CHELLAMMAL 0.4 0.4 126 122 38 36 45 41 12 12 0.6 0.6 NIL NIL NIL NIL 1-2 epi 
cells 
1-2 epi 
cells 
8 3496 
 
SUMATHI 0.6 0.5 148 139 26 24 52 52 8 9 0.8 0.6 NIL NIL NIL NIL 2-3- epi 
cells 
1-2 epi 
cells 
9 3747 
 
PAZHANI RAJ 0.2 0.2 90 95 8 7 12 11 8 8 0.6 0.4 NIL NIL NIL NIL 1-2 pus 
cells 
0-1 pus 
cell 
10 4323 
 
BILLIAMMA 
 
0.6 0.6 78 76 15 16 13 13 16 15 1.0 1.0 NIL NIL NIL NIL 0-1 epi 
cells 
0-1 epi 
cells 
11 1185 
/360 
UMA 0.2 0.1 65 62 7 6 43 41 18 16 0.8 0.7 NIL NIL NIL NIL 1-2 pus 
cells 
1-2 pus 
cells 
12 1198 
/795 
SELVAKUMAR 0.8 0.6 137 138 12 12 39 35 11 10 0.6 0.6 NIL NIL NIL NIL 2-3- epi 
cells 
1-2 epi 
cells 
13 1203 
/886 
GOWRI 0.6 0.4 127 127 10 10 27 26 15 14 0.9 0.8 NIL NIL NIL NIL 2-3 pus 
cells 
1-2 pus 
cells 
14 1238 
/1979 
RASAPPA 0.2 0.2 134 119 25 23 26 27 7 6 0.4 0.3 NIL NIL NIL NIL 1-2 epi 
cells 
1-2 epi 
cells 
15 1302 
/4372 
ARUNA 0.4 0.5 132 127 39 31 17 16 9 8 0.6 0.5 NIL NIL NIL NIL 2-3- epi 
cells 
1-2 epi 
cells 
16 1316 
/4776 
BRINDHA 0.6 0.4 90 92 41 37 37 37 15 14 0.6 0.7 NIL NIL NIL NIL 1-2 pus 
cells 
0-1 pus 
cells 
17 1462 
/632 
DHANSHERA 0.2 0.2 86 82 30 29 34 32 16 15 0.6 0.6 NIL NIL NIL NIL 1-2 pus 
cells 
0-1 pus 
cell 
18 1465 
/2829 
LAKSHMI BAI 0.6 0.7 79 72 12 13 48 47 12 12 1.2 1.1 NIL NIL NIL NIL 0-1 epi 
cells 
0-1 epi 
cells 
19 1511 
/2793 
RAMANI 0.2 0.1 59 47 14 12 23 24 16 16 0.6 0.6 NIL NIL NIL NIL 1-2 pus 
cells 
0-1 pus 
cells 
20 1517 
/2775 
KAMATCHI  
0.1 
 
0.1 
 
78 
 
68 
 
21 
 
17 
 
22 
 
22 
 
13 
 
12 
 
0.7 
 
0.6 
 
NIL 
 
NIL 
 
NIL 
 
NIL 
1-2 pus 
cells 
1-2 pus 
cells 
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GROUP II SUBJECT : LAB INVESTIGATION 
 
 
S. 
NO 
 
 
 
OP NO  
/IPNO 
 
 
 
 
NAME 
 
                               LIVER  FUNCTION TEST 
 
 
RENAL FUNCTION TEST 
 
URINE ANALYSIS 
 
S.Bilurubin 
(mg/dl) 
 
Alkaline 
Phosphatase 
(U/L) 
 
SGOT 
(U/L) 
 
SGPT 
(U/L) 
 
UREA 
(mg/dl) 
 
CREATININE 
(mg/dl) 
 
Albumin 
 
Sugar 
 
Deposits 
BT AT BT AT BT 
 
AT BT 
 
AT BT AT BT AT BT AT BT AT BT AT 
1 5947 SAJID IBRAHIM 0.4 0.3 80 87 23 21 37 36 13 14 0.8 0.8 NIL NIL NIL NIL 2-3 epi 
cells 
2-3 epi 
cells 
2 7710 KOLAVIZHI 0.7 0.6 138 148 41 35 29 27 19 15 0.6 0.5 NIL NIL NIL NIL 1-2 epi 
cells 
1-2 epi 
cells 
3 9029 MEERA 0.2 0.2 126 122 6 5 44 46 12 15 0.9 0.9 NIL NIL NIL NIL 2-3- epi 
cells 
1-2 epi 
cells 
4 9572 SARATHA    0.1 0.1 148 130 8 7 14 13 8 11 1.4 1.2 NIL NIL NIL NIL 1-2 pus 
cells 
0-1 pus 
cell 
5 5639 POONKUZHALI 0.3 0.2 90 98 17 13 37 37 13 12 0.3 0.3 NIL NIL NIL NIL 0-1 epi 
cells 
0-1 epi 
cells 
6 6405 THENAVAN 0.7 0.6 78 79 16 14 19 19 8 7 0.8 0.7 NIL NIL NIL NIL 1-3 epi 
cells 
1-4 epi 
cells 
7 6419 TAMIL SELVI 0.6 0.2 65 67 8 8 22 22 17 16 0.6 0.6 NIL NIL NIL NIL 1-2 epi 
cells 
1-2 epi 
cells 
8 2654 DEEPA 0.8      0.1 137 138 24 21 39 39 16 16 0.9 0.8 NIL NIL NIL NIL 1-2 pus 
cells 
0-1 pus 
cell 
9 3601 NAGAVALLI 0.6 0.6 148 139 38 36 40 37 19 18 0.4 0.3 NIL NIL NIL NIL 0-1 epi 
cells 
0-1 epi 
cells 
10 8898 KALAIVANI 0.2 0.3 78 76 26 24 51 49 12 12 0.6 0.6 NIL NIL NIL NIL 1-2 pus 
cells 
1-2 pus 
cells 
11 1735 
/961 
KATHAVARAYA
N 
0.4      0.1 65 62 8 7 19 18 11 9 0.6 0.7 NIL NIL NIL NIL 2-3- epi 
cells 
1-2 epi 
cells 
12 1826 
/4768 
MALLIGA 0.3 0.4 137 138 15 16 23 22 09 08 0.9 0.8 NIL NIL NIL NIL 0-1 epi 
cells 
1-2 pus 
cells 
13 1836 
/5595 
KOMALA DEVI 0.3 0.4 78 68 17 15 08 08 10 12 0.8 0.8 NIL NIL NIL NIL 1-2 pus 
cells 
1-2 pus 
cells 
14 1939 
/460 
AGAMATH ALI 0.4 0.5 135 107 9 7 24 23 08 06 1.2 1.2 NIL NIL NIL NIL 1-2 epi 
cells 
1-2 epi 
cells 
15 1993 
/2304 
PRABHU 0.5 0.2 146 139 13 11 36 36 14 13 1.1 1.0 NIL NIL NIL NIL 2-3 epi  
cells 
1-2 epi 
cells 
16 2279 
/5876 
AMUDHAVALLI 0.6 0.5 98 72 42 37 45 44 19 16 0.9 0.8 NIL NIL NIL NIL 1-2 epi 
cells 
1-2 pus 
cells 
17 2337 
/9287 
JAYANTHI 0.6 0.6 69 57 28 29 52 51 13 11 0.8 0.6 NIL NIL NIL NIL 1-2 epi 
cells 
1-2 epi 
cells 
18 2341 
/9396 
BHUVANESWAR
I 
0.2 0.2 132 134 37 33 36 36 12 09 0.7 0.7 NIL NIL NIL NIL 2-3- epi 
cells 
1-2 epi 
cells 
19 2476 
/6035 
VIJAYARANI 0.6 0.5 104 101 22 18 17 16 13 12 0.6 0.7 NIL NIL NIL NIL 1-2 pus 
cells 
1-2 pus 
cells 
20 3093 
/7483 
SASIKUMAR 0.2 0.3 98 91 26 27 09 09 14 14 0.9 0.9 NIL NIL NIL NIL 2-4 pus 
cells  
1-2 pus 
cells 
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BIOSTATISTICS REPORTS 
CLINICAL PROGNOSIS- TREATMENT FOR SAGANA VATHAM 
IMPROVEMENT IN PATIENTS TREATED WITH POORANATHI 
CHOORANAM (INT) - GROUP I PATIENTS 
The most popular non parametric statistical tool, namely, Mc Nemar Test 
analysis has been employed to analyses the effectiveness with the help of a 
hypothesis. 
 
IMPROVEMENT OF GROUP I SUBJECTS:  
 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Neck pain 20(100) 6(30)** 
2. Radiating pain in upper 
limbs 
12(60) 2(10)** 
3. Stiffness of  neck 5(25) 1(5)* 
4. Numbness 7(35) 1(5)** 
5. Giddiness 3(15) 1(5)* 
6. Tenderness 4(20) 1(5)* 
7. Movement restriction 1(5) 1(5) 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features except movement 
restriction. So there is significant reducing of clinical features among the patients for 
the treatment of Saganavadham (Cervical spondylosis). Hence it is concluded that the 
treatment was effective and significant 
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GROUP II PATIENTS - IMPROVEMENT IN PATIENTS TREATED WITH 
“POORANATHI CHOORANAM” (Int), “VALLI KUTHALUKU ULLI ENNAI 
” (Ext),  and “OTTRADAM ” (Therapy). 
The most popular non parametric statistical tool, namely, Mc Nemar Test 
analysis has been employed to analyses the effectiveness with the help of a 
hypothesis. 
 
IMPROVE MENT OF GROUP II SUBJECTS:  
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Neck pain 20(100) 1(5)** 
2. Radiating pain in upper 
limbs 
10(50) 1(5)** 
3. Stiffness of  neck 9(45) 1(5)** 
4. Numbness 7(35) 0(0)** 
5. Giddiness 4(20) 0(0)** 
6. Tenderness 3(15) 0(0)** 
7. Movement restriction 1(5) 0(0)* 
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 20 
Inference:  
Since the p value is significant in all clinical features. So there is significant 
reducing of clinical features among the patients for the treatment of Saganavadham 
(Cervical spondylosis).Hence it is concluded that the treatment was effective and 
significant. 
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GROUP I SUBJECTS: LIVER FUNCTION TEST 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 SGOT 21.25±10.71 19.50±9.50 <0.05 
2 SGPT 29.70±13.07 28.80±12.82 <0.05 
3 Alkaline Phosphatase 96.70±30.65 93.20±30.94 <0.05 
4 T.Bilirubin 0.42±0.21 0.33±0.20 <0.05 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
 
 
GROUP II SUBJECTS : LIVER FUNCTION TEST 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 SGOT 21.20±11.54 19.20±10.66 <0.001 
2 SGPT 30.05±13.45 29.40±13.36 <0.05 
3 Alkaline Phosphatase 107.50±30.85 102.65±30.90 <0.05 
4 T.Bilirubin 0.43±0.20 0.34±0.18 0.061 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
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GROUP I SUBJECTS : RFT 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 13.10±3.55 12.35±3.31 <0.001 
2 Creatinine 0.73±0.22 0.67±0.22 <0.05 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant.  
 
GROUP II SUBJECTS :RFT 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 13.00±3.56 12.30±3.29 0.110 
2 Creatinine 0.79±0.26 0.74±0.23 <0.05 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
GROUP I SUBJECTS:BLOOD INVESTIGATION 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 11.07±1.12 11.60±1.04 <0.05 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP II SUBJECTS:BLOOD INVESTIGATION 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Hb 11.23±1.24 12.05±0.87 <0.001 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
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PAIN ASSESSMENT BASED ON VISUAL ANALOG SCALE 
GROUP I SUBJECTS 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 PAIN Scale 7.20±1.57 2.15±2.92 <0.001  
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 represents statistically 
significant. 
 
GROUP II SUBJECTS:  
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 PAIN Scale 7.55±1.57 0.00±0.00 <0.001  
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 represents statistically 
significant. 
    Since the P value is highly significant (<0.001) in 2 groups. So there is significant 
reducing of PAIN Scale among the patients for the treatment of Saganavadham 
(Cervical spondylosis).Hence it is concluded that the treatment was effective and 
significant.  
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6. DISCUSSION 
 In Siddha system of medicine, the disease “SAGANA VATHAM” is brought 
under the types of vadha diseases. And it is correlated with “Cervical spondylosis”. 
Cervical spondylosis is defined as “ARTHROSIS” Of the posterior intervertebral joints 
in the cervical   vertebrae.It is common in the middle aged and in the elderly particularly 
in those whose occupation involves a posture of prolonged neck flexion. This is 
characterised by   pain in nape of the neck (local /referred pain),radiating pain in upper 
limbs, tenderness, Numbness, Stiffness of neck, Restriction of movements of neck, 
Giddiness, Sensory loss & paraesthesia in the corresponding dermatomes (due to sensory 
root involvement), Weakness of muscles supplied (due to motor root involvement). 
The present study was conducted to evaluate the safety and therapeutic efficacy of 
“Pooranathi Chooranam”(Internal medicine) and “Vali kuthaluku ulli ennai” (External 
medicine) and to compare along with  the effect of “Veppam Pinnakku Ottradam” 
(External therapy) in Sagana vatham at  OPD& IPD of PG Department of Varmam, Pura 
maruthuvam and Yoga maruthuvam, GSMC attached with Aringnar Anna Government 
Hospital of Indian medicine and Homoeopathy. 
In the present study 40 patients between the age group of 20-60 years as per 
inclusion criteria as mentioned above were categorized into three groups. The study 
period was 1 year. The groups were designated as G1 was subjected to Pooranathi 
chooranamalone, G2 was subjected to Pooranathi chooranam (Int), &Vali kuthaluku ulli 
ennai (Ext), “Veppam Pinnakku Ottradam” (External therapy) Observation period was 
fixed at 48 days. 
Progress of the patients was followed and documented regularly. Various 
criterialike Distribution of Gender, Age, Diet, Occupational & Socio-Economic status 
wereassessed. Clinical manifestation and assessment of the enhancement in the prognosis 
of the disease Saganavadham with the trial drugs along with ottradam were taken into 
account for evaluating the efficacy of the trial drugs. 
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AGE DISTRIBUTION 
Among 40 cases, 10% of cases were in the 20-30 age group. 35%, 40 % and 15% 
of cases were in the age of 31-40, 41-50 and 51-60 respectively 
 
GENDER 
Among 40 cases, 13% of cases were Males and 67.5% of patients were females.  
 
OCCUPATIONAL DISTRIBUTION 
           Among 40 cases, 45% of cases were House wives, 12.5% of cases were Teachers, 
10% were Tailor, 7.5% of cases were IT employees And Coolies. Painters, Salesmans & 
Drivers were 5% each. Electricians were 2.5% each. 
 
SOCIO ECONOMIC STATUS 
          Among 40 cases, 20% of cases were Lower, 35% of cases were upper lower, 
32.5% were Lower middle, 10% of cases were Upper middle And 2.5% cases were 
Upper group. 
 
DISTRIBUTION OF DIET 
            Among 40 cases, 80% of cases were consuming mixed diet and 20% were 
Vegetarian 
 
DURATION OF ILLNESS 
            Out of 40 patients subjected in the present study, 25% belonged to less than 1 
month of illness and others were 20% in 1-3 months, 25% in 4-6 months, 42.5% in 7 
months-12 month, 5% in 13-24 months and 25-36 months of illness. 
 
DISTRIBUTION AMONG PARUVAKAALANGAL 
            Among 40 patients,  12.5%, 20%, 2.5% , 30% and 35%  of patients came in Kaar, 
koothir, Pinpani, Ilavenil and Muthuvenil kaalam. No cases were came in Munpani 
kaalam. 
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DISTRIBUTION AMONG THINAI 
              Out of 40 patients, 90% of patients belongs to NeithalNilam and 5% of patients 
belong to Marutha & Kurinji Nilam 
 
DISTRIBUTION AMONG KAALAM 
              Out of 40 patients, 15% of patients were belonged Vathakaalam and 85% 
belonged to Pithakaalam 
 
DISTRIBUTION OF VATHAM 
              Out of 40 Patients, Vyanan and Samanan were affected in all the patients. 
Abanan and udanan were affected in 45% and 5% of patients respectively. 
 
DISTRIBUTION OF PITHAM 
             Out of 40 patients, Anarpitham was affected in 22.5% of patients and 
Saathagapitham was affected in all the patients (100%). 
 
DISTRIBUTION OF KABAM 
              Out of 40 patients, Santhigam was affected in all patients (100%).  
 
DISTRIBUTION OF ENVAGAI THERVU 
              Out of 40 patients, Nadi was affected in100% of patients, Naa was affected in 
7.5% of patients and Malam was affected in45% of patients. 
 
NEIKKURI 
Out of 40 patient’s urine sample vathaneer was present in 72.5% of patient’s urine 
sample, Pithaneer was present in 20% of patient’s urine sample and Kabaneer was 
present in 7.5% of urine sample. 
 
DISTRIBUTION OF NADI 
 Out of 40 patients, Vathapithanadi, Pithavathanadi and vathanadi were present in 
54.3%, 30% and 16.6% of patients. 
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TREATMENT OUTCOME: 
 The clinical study of Pooranathi chooranam alone, Pooranathi chooranam, Vali 
kuthaluku ulli ennai (ext)  combined therapy  with Ottradam was done in two groups 
each comprising 20 patients. The patient’s response to Pooranathi chooranam alone 
(G1), Vali kuthaluku ulli ennai (Ext), “Veppam Pinnakku Ottradam” (External therapy) 
(G2)  was tried on 40 patients in two groups of 20 each the following inferences were 
made on the basis of Visual analog scale.  
 
In Group I, 60% of patients had Good improvement, 20% of patients had 
moderate  and 15% mild improvement  and 5% of patients had No improvement. 
In Group II, 95% of patients had Good improvement, 5% of patients had 
moderate improvement. None of the patients showed Mild and No improvement. 
The result of subjective parameters had revealed that Group 2 have shown 
significant improvement than Group I in reducing all symptoms of Saganavatham which 
is 95% respectively.  
 Thus, on comparing the two Groups, Group 3 which was given the combined 
therapy of Pooranathi chooranam, Vali kuthaluku ulli ennai (ext)  combined therapy  
with “Veppam Pinnakku Ottradam” had shown significant improvement with 
symptomatic management in Saganavatham.   
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6. DISCUSSION 
 In Siddha system of medicine, the disease “SAGANA VATHAM” is brought 
under the types of vadha diseases. And it is correlated with “Cervical spondylosis”. 
Cervical spondylosis is defined as “ARTHROSIS” Of the posterior intervertebral joints 
in the cervical   vertebrae.It is common in the middle aged and in the elderly particularly 
in those whose occupation involves a posture of prolonged neck flexion. This is 
characterised by   pain in nape of the neck (local /referred pain),radiating pain in upper 
limbs, tenderness, Numbness, Stiffness of neck, Restriction of movements of neck, 
Giddiness, Sensory loss & paraesthesia in the corresponding dermatomes (due to sensory 
root involvement), Weakness of muscles supplied (due to motor root involvement). 
The present study was conducted to evaluate the safety and therapeutic efficacy of 
“Pooranathi Chooranam”(Internal medicine) and “Vali kuthaluku ulli ennai” (External 
medicine) and to compare along with  the effect of “Veppam Pinnakku Ottradam” 
(External therapy) in Sagana vatham at  OPD& IPD of PG Department of Varmam, Pura 
maruthuvam and Yoga maruthuvam, GSMC attached with Aringnar Anna Government 
Hospital of Indian medicine and Homoeopathy. 
In the present study 40 patients between the age group of 20-60 years as per 
inclusion criteria as mentioned above were categorized into three groups. The study 
period was 1 year. The groups were designated as G1 was subjected to Pooranathi 
chooranamalone, G2 was subjected to Pooranathi chooranam (Int), &Vali kuthaluku ulli 
ennai (Ext), “Veppam Pinnakku Ottradam” (External therapy) Observation period was 
fixed at 48 days. 
Progress of the patients was followed and documented regularly. Various 
criterialike Distribution of Gender, Age, Diet, Occupational & Socio-Economic status 
wereassessed. Clinical manifestation and assessment of the enhancement in the prognosis 
of the disease Saganavadham with the trial drugs along with ottradam were taken into 
account for evaluating the efficacy of the trial drugs. 
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AGE DISTRIBUTION 
Among 40 cases, 10% of cases were in the 20-30 age group. 35%, 40 % and 15% 
of cases were in the age of 31-40, 41-50 and 51-60 respectively 
 
GENDER 
Among 40 cases, 13% of cases were Males and 67.5% of patients were females.  
 
OCCUPATIONAL DISTRIBUTION 
           Among 40 cases, 45% of cases were House wives, 12.5% of cases were Teachers, 
10% were Tailor, 7.5% of cases were IT employees And Coolies. Painters, Salesmans & 
Drivers were 5% each. Electricians were 2.5% each. 
 
SOCIO ECONOMIC STATUS 
          Among 40 cases, 20% of cases were Lower, 35% of cases were upper lower, 
32.5% were Lower middle, 10% of cases were Upper middle And 2.5% cases were 
Upper group. 
 
DISTRIBUTION OF DIET 
            Among 40 cases, 80% of cases were consuming mixed diet and 20% were 
Vegetarian 
 
DURATION OF ILLNESS 
            Out of 40 patients subjected in the present study, 25% belonged to less than 1 
month of illness and others were 20% in 1-3 months, 25% in 4-6 months, 42.5% in 7 
months-12 month, 5% in 13-24 months and 25-36 months of illness. 
 
DISTRIBUTION AMONG PARUVAKAALANGAL 
            Among 40 patients,  12.5%, 20%, 2.5% , 30% and 35%  of patients came in Kaar, 
koothir, Pinpani, Ilavenil and Muthuvenil kaalam. No cases were came in Munpani 
kaalam. 
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DISTRIBUTION AMONG THINAI 
              Out of 40 patients, 90% of patients belongs to NeithalNilam and 5% of patients 
belong to Marutha & Kurinji Nilam 
 
DISTRIBUTION AMONG KAALAM 
              Out of 40 patients, 15% of patients were belonged Vathakaalam and 85% 
belonged to Pithakaalam 
 
DISTRIBUTION OF VATHAM 
              Out of 40 Patients, Vyanan and Samanan were affected in all the patients. 
Abanan and udanan were affected in 45% and 5% of patients respectively. 
 
DISTRIBUTION OF PITHAM 
             Out of 40 patients, Anarpitham was affected in 22.5% of patients and 
Saathagapitham was affected in all the patients (100%). 
 
DISTRIBUTION OF KABAM 
              Out of 40 patients, Santhigam was affected in all patients (100%).  
 
DISTRIBUTION OF ENVAGAI THERVU 
              Out of 40 patients, Nadi was affected in100% of patients, Naa was affected in 
7.5% of patients and Malam was affected in45% of patients. 
 
NEIKKURI 
Out of 40 patient’s urine sample vathaneer was present in 72.5% of patient’s urine 
sample, Pithaneer was present in 20% of patient’s urine sample and Kabaneer was 
present in 7.5% of urine sample. 
 
DISTRIBUTION OF NADI 
 Out of 40 patients, Vathapithanadi, Pithavathanadi and vathanadi were present in 
54.3%, 30% and 16.6% of patients. 
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TREATMENT OUTCOME: 
 The clinical study of Pooranathi chooranam alone, Pooranathi chooranam, Vali 
kuthaluku ulli ennai (ext)  combined therapy  with Ottradam was done in two groups 
each comprising 20 patients. The patient’s response to Pooranathi chooranam alone 
(G1), Vali kuthaluku ulli ennai (Ext), “Veppam Pinnakku Ottradam” (External therapy) 
(G2)  was tried on 40 patients in two groups of 20 each the following inferences were 
made on the basis of Visual analog scale.  
 
In Group I, 60% of patients had Good improvement, 20% of patients had 
moderate  and 15% mild improvement  and 5% of patients had No improvement. 
In Group II, 95% of patients had Good improvement, 5% of patients had 
moderate improvement. None of the patients showed Mild and No improvement. 
The result of subjective parameters had revealed that Group 2 have shown 
significant improvement than Group I in reducing all symptoms of Saganavatham which 
is 95% respectively.  
 Thus, on comparing the two Groups, Group 3 which was given the combined 
therapy of Pooranathi chooranam, Vali kuthaluku ulli ennai (ext)  combined therapy  
with “Veppam Pinnakku Ottradam” had shown significant improvement with 
symptomatic management in Saganavatham.   
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7. SUMMARY 
 40 cases with Saganavadham were diagnosed clinically based on yugi 800 and 
admitted in the inpatient ward and outpatient ward of post graduate department of 
Varmammaruthuvam, Pura maruthuvam & Yoga maruthuvam, GSMC attached with 
Aringar Anna Hospital for Indian medicine and Homeopathy, Chennai and treated by the 
trial medicines 
           The aim of the study is to  evaluate the safety and efficacy of “Pooranathi 
Chooranam” (Int) and “Valik uthaluku ulli ennai” (Ext) and to compare along with  the 
effect of “Veppam Pinnakku Ottradam” therapy intervention for saganavatham. 
The study was started after analyzing the internal and external medicine along 
with ottradam therapy has been approved by IEC committee (GSMC-CH-ME-
2/011/2017). The clinical trial is also registered in Clinical Trial Registry of India 
(CTRI/2018/05/013642). Acute toxicity study was carried out to confirm the safety of the 
drug by IAEC Committee (LV/04/CLBMCP/2018). Standardization and Quality 
Evaluation of the drug was done. 
Before conducting the clinical trial, the details about the trial drug and my study 
was informed to the patients in their vernacular language and their signature were 
obtained in the consent forms. Separate Proforma was maintained for each and every 
patient. 
            The clinical study of Pooranathi chooranam alone (Group1) and Pooranathi 
Chooranam and Vali kuthaluku ulli ennai and “Veppam Pinnakku Ottradam” (Group 2) 
was done in three groups each comprising 20 patients. The inferences were made. All two 
groups shown statistically significant improvement. 
             Primary outcome was assessed by Visual Analog Scale (Universal Pain 
Assessment Scale). Secondary outcome i.e reduction in clinical parameters was also 
assessed. Among the three groups Group 2 shown better improvement. Statistical 
analysis was performed to assess the significance of the clinical trial. 
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8. CONCLUSION 
Siddha Polyherbal preparation Pooranathi Chooranam was chosen for studying its 
efficacy on Saganavatham as internal medicine. 
Heavy metal analysis of PC reveals that within permitted limit.  
Phytochemical study shown that the trial drug PC has Alkaloids, saponins, tanins, 
glycosides, flavonoids, phenols, steroids, carbohydrates and proteins. 
The acute & Sub acute toxicity study reveals that the trial drugs PC is safe, Sub 
acute toxicity study two doses were administrated orally for 28 days. Animals were 
observed for physiological and behavioural changes food and water, intake body, weight, 
mortality. All the animals were sacrificed, the changes in organ weight and histology 
were examined no mortality were observed and no treatment related changes seen. Hence 
the siddha trial drugs PC is safe in animal models.  
Pharmacological study shown that the drug Pooranathi chooranam has significant 
Anti-inflammatory and Analgesic activity 
 In Group I, 60% of patients had Good improvement, 20% of patients had 
moderate and 15% of patient mild improvement and 5% of patients had No improvement. 
           In Group II, 95% of patients had Good improvement, 5% of patients had moderate 
improvement. None of the patients showed Mild and No improvement. 
Group II had shown better results over the other two groups. 
During the course of treatment there were no adverse effects or unwanted drug 
reactions in GIT,CVS, RS & Excretory systems. 
Hence it is concluded that the combined therapy of  Pooranathi chooranam (Int), 
Vali kuthaluku ulli ennai (ext)  combined therapy with “Veppam Pinnakku Ottradam” 
gives significant improvement  in the treatment of Saganavatham (Cervical Spondylosis) 
shows  perceived effectiveness, safety &lower cost. 
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      POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
 AN OPEN  CLINICAL  EVALUTION ON SAGANAVATHAM (CERVICAL 
SPONDYLOSIS) WITH THE  SIDDHA TRIAL DRUG  “POORANATHI 
CHOORANAM”  (INTERNAL),  “VALI KUTHALUKU ULLI ENNAI”  
(EXTERNAL) AND  “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY). 
                 FORM l - SCREENING AND SELECTION PROFORMA 
 
1. OP NO 
2. NAME: 
3. AGE:                                    4. GENDER:  
5. OCCUPATION:                 6. INCOME 
 7. ADDRESS: 
 
       8. CONTACT NO:              
INCLUSION CRITERIA 
 Age      :  between 20-60 years                                                          YES/NO 
 Sex      :  Both male and female                                                         YES/NO      
 Muscle spasms in neck and shoulders     YES/NO 
 Complaint about pain behind the neck in the area of trapezius          YES/NO                                        
 Radiating pain to the upper limbs upto the fingers.                            YES/NO 
  Numbness and weakness in arms, hands and fingers                         YES/NO 
 Limitation of movements                                                                    YES/NO 
 Giddiness         YES/NO 
 Willing to sign the consent form        YES/NO 
EXCLUSION CRITERIA 
(History of) 
 Cervical rib 
 Trauma 
 Spina bifida  
 Cardiac disease 
 Fracture  
 Ankylosing spondylitis 
 Malignancy  
 Pregnancy and Lactation  
 Tuberculosis in spine 
 Adhesive capsulitis 
 Carpal tunnel syndrome 
 Straight cervical spine  
 Patient with any other serious systemic illness. 
 
ADMITTED TO TRIAL: 
                          
 YES                        NO                 
 
      If yes,             OPD/IPD                    
 
Date:  
                                                                                           Signature of the Guide: 
 Station: 
              Signature of the Investigator:   
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                                                    CHENNAI – 600 106  
            POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN  OPEN  CLINICAL  EVALUTION ON SAGANAVATHAM (CERVICAL     
SPONDYLOSIS) WITH THE  SIDDHA TRIAL DRUG  “POORANATHI   
CHOORANAM”  (INTERNAL),  “ VALI  KUTHALUKU ULLI ENNAI”  
(EXTERNAL) AND “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY). 
FORM lI -HISTORY TAKING PROFORMA 
 
1. SERIAL NO OF THE CASE: …….   2.OP/IP NO: .............................................. 
  
3. NAME: ………………………………………… 4. AGE: …….. 5. GENDER: …….. 
5. OCCUPATION: ………………………………      6. INCOME:   ……................ 
7. COMPLAINTS & DURATION:   
 
8. CHIEF COMPLAINTS WITH DURATION 
 
9. HISTORY OF PRESENT ILLNESS 
 
1. Onset of disease  :            Acute   Insidious 
2. Duration of disease  : 
3. Treatment given so far :  Ayurvedic medicine  Modern Medicine 
 
Unani    Homeopathy 
 
                                                                                                                                                          
10. PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES, SPECIFY 
DURATION/QUANTITY 
Smoking    
Tobacco Chewing    
Alcoholism    
Narcotic drugs    
 
11. DRUG HISTORY: 
12. HISTORY OF PREVIOUS ILLNESS/PELVIC SURGERY: 
13. DIETARY HABIT:     
             1. Vegetarian              
             2. Non-vegetarian  
14. FAMILY HISTORY: 
               Whether this problem runs in family? 
                                         1. Yes                               2.No         
If yes, mention the relationship of affected person(s) --------------------- 
History of previous investigations if any ------------------------------ 
15. MENSTURAL HISTORY: 
Date:        Signature of the Guide: 
       
Station:       Signature of the Investigator: 
                                                     
             Signature of the Investigator:   
 
                         GOVERNMENT SIDDHA MEDICAL COLLEGE 
             ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                                                   CHENNAI – 600 106 
            POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM  
AN OPEN  CLINICAL  EVALUTION ON SAGANAVATHAM (CERVICAL 
SPONDYLOSIS) WITH THE  SIDDHA TRIAL DRUG  “POORANATHI 
CHOORANAM”  (INTERNAL),   “ VALI  KUTHALUKU ULLI ENNAI”  
(EXTERNAL) AND “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY). 
   
FORM III - CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
1. SI NO: --------    2. OP NO: -------------       3. IP NO:----------  4.BED NO:--------- 
5. NAME :----------------------          
6.  RELIGION : H / C / M / O                        
7. AGE/GENDER :-------------             8. OCCUPATION: -------------------------         
9. CONTACT NUM: ------------------------ 
10. DATE OF INITIAL ASSESSEMENT: -----------------------   
       
  
SIDDHA SYSTEM OF EXAMINATION 
 
1. THEGI (BODY CONSTITUTION): 
       1. Vatha udal 
       2. Pitha udal 
       3. Kaba udal 
       4. Thontha udal 
 
 
 
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):  
        1. Kurinji  
       2. Mullai 
        3. Marutham 
            4. Neithal 
        5. Paalai  
3. KAALAM: 
1. Kaar kaalam    (Aavani-Puratasi) 
2. Koothir kaalam     (Ippasi-Kaarthigai) 
  3. Munpani kaalam     (Maargazhi-Tai) 
4. Pinpani kaalam       (Maasi-Panguni) 
5. Ilavenil kaalam        (Chithirai-Vaigasi) 
6. Muthuvenil kaalam    (Aani-Aadi) 
4. GUNAM: 
1. Sathuvam 
2. Rasatham 
3. Thamasam 
 
5. PORI PULANGAL (SENSORY ORGANS):                  
                         Normal     Affected   
1. Mei         ................................................................. 
2. Vaai   (Naaku)   .................................................................. 
3. Kan                                  .................................................................. 
4. Mookku                          ................................................................. 
5. Sevi                                      .................................................................. 
 
 
6. KANMENDRIYAM (MOTOR ORGANS) :          
 Normal   Affected  
1. Vaai                                    ................................................................. 
2. Kaal                                  ................................................................. 
3. Kai                                     ................................................................. 
4. Eruvaai                                 ................................................................. 
5. Karuvaai                               ................................................................  
7. KOSANGAL (SHEATH):          
    Normal  Affected  
1. Annamaya kosam  .      ....                ............................................................ 
2. Pranamaya kosam      ............................................................ 
3. Manomaya kosam   .   ............................................................ 
4. Vignanamaya kosam     ....      ............................................................. 
5. Anandhamaya kosam     ....      ............................................................. 
8. UYIR THATHUKKAL (THREE HUMOURS): 
8a.VALI:              Normal   Affected 
1. Praanan                          ................................................................. 
2. Abaanan                                ................................................................. 
3. Viyaanan                                ................................................................. 
4. Uthaanan                                 .................................................................. 
5. Samaanan                                 ................................................................. 
6. Naagan                                     .................................................................. 
7. Koorman                                  .................................................................. 
8. Kirukaran                                 ................................................................. 
9. Devathathan                              ................................................................. 
10. Dhananjayan  .            ................................................................ 
 
8b. AZHAL:              Normal    Affected 
1. Analam                                   ................................................................. 
2. Ranjagam                              ................................................................. 
3. Saathagam                              ................................................................. 
4. Aalosagam                               ................................................................. 
5. Praasagam                                .................................................................. 
 
8c.IYAM:              Normal    Affected 
1. Avalambagam                         ................................................................. 
2. Kilethagam                              ................................................................. 
3. Pothagam                                 ................................................................. 
4. Tharpagam                               ................................................................. 
5. Santhigam                                ................................................................. 
 
9. EN VAGAI THERVU (EIGHT FOLDS OF EXAMINATION): 
1.Naadi     :            ………………………................. 
2.Parisam :            ………………………................. 
3.Naa         :           ............……………….................. 
4.Niram     :           .....……………………................. 
5.Mozhi     :           .....……………………................. 
6.Vizhi       :           ...................................................... 
7.Malam    :           ..................................................... 
8. Moothiram :      …………………………………. 
         8a.Neerkuri: 
Niram      :        1.Whitish                               2. Yellowish     
   3.Straw coloured                    4. Crystal clear 
 
   Edai     :  1.Present              2.Absent   
Manam    :               1.Nil                     2.Reduced                    3. Increased 
Nurai       :                 1. Normal             2. Increased                  3. Decreased  
Enjal        : 
 
 8b: Neerkuri (Oil –in urine sign): 
        Vatha Neer                                         Pitha Neer              Kaba Neer 
10. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS):       
     Normal    Affected   
 1. Saaram                                                 ..................................................... 
2. Senneer    ..           .................................................... 
3. Oon                                                  ..................................................... 
4. Kozhuppu                                      .................................................... 
5. Enbu      ……………………………........ 
6.Moolai                                               .................................................... 
7. Sukkilam / Suronitham         ................................................... 
 
GENERAL EXAMINATION: 
1. Body weight [Kg]                :                      
2. Height [cm]                        :                        
3. Body Temperature [F]        :   
4. Blood Pressure (mmHg)  :      
5. Pulse Rate /min.   : 
6. Heart Rate / min.    : 
7. Respiratory Rate /min.             : 
 
 
         Yes              No   
8. Pallor  :   
9. Jaundice          :   
10. Clubbing :  
11. Cyanosis : 
12. Pedal Oedema   :  
13. Lymphadenopathy  :           
14. Jugular venous pulsation :  
VITAL ORGAN EXAMINATION:                                                      
           Normal          Abnormal 
1.  Heart  
2. Lungs  
3. Brain 
4. Liver 
5. Kidney 
6. Spleen 
7. Stomach   
 
SYSTEMIC EXAMINATION: 
            Normal          Abnormal 
1. Cardio-vascular system 
2. Respiratory system         
3. Gastro intestinal system 
4. Central nervous system 
5. Genital urinary system     
6.  Endocrine system        
CLINICAL ASSESSMENT:   
                              
COMPLAINTS 
          0
th
 day          7
th
 day    14
th
     day           21
st
  day 
Pain in neck     
Pain in shoulder     
Nature of pain     
Onset of pain     
Radiating pain in right 
upper limb 
    
Radiating pain in left upper 
limb 
    
Numbness     
Tenderness      
Restriction of movements     
Burning sensation     
Giddiness     
 
 
 
 
 
 
 
 
 
 
 
 
                              
COMPLAINTS 
           28
th
 
day 
         35
th
 day           42
nd
 
day 
           49
th
 day 
Pain in neck     
Pain in shoulder     
Nature of pain     
Onset of pain     
Radiating pain in right upper 
limb 
    
Radiating pain in left upper 
limb 
    
Numbness     
Tenderness      
Restriction of movements     
Burning sensation     
Giddiness     
 
PAIN ASSESMENT: VISUAL ANALOGUE SCALE:  
0 – nil ;  + - mild ;  ++ - moderate ; +++ - severe 
 
 
 
 
CLINICAL EXAMINATION:   
 
I. INSPECTION     
 0
th
  day 7
th
 day 14
th
 
day 
21
st
  
day 
28
th
  
day 
35
th
 
day 
42
nd
 
day 
 49
th
 
day  
ATTITUDE         
MUSCLE 
WASTING 
        
SWELLING         
         
 
 
 II PALPATION:   
 0
th
  
day 
7
th
 day 14
th
 
day 
21
st
  
day 
28
th
  
day 
35
th
 
day 
42
nd
 
day 
 49
th
 
day  
Tenderness         
Muscle spasm         
Local heat         
Local 
lymphadenopathy 
 
        
Pitting oedema         
Joint stiffness         
 
 
 
III. MOVEMENTS: 
 0
th
  day 7
th
 day 14
th
 day 21
st
  
day 
28
th
  
day 
35
th
 day 42
nd
 
day 
 49
th
 
day  
Stiffness         
Restriction of movements: 
Rotation         
Flexion         
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bending 
        
 
 
 
 
 
 
Date:                                                        Signature of the guide: 
  
Station:                                                                                 
                                                                                         Signature of the Investigator:  
                       GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI 106 
          POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM    
                FORM IV : LABORATORY INVESTIGATIONS PROFORMA 
AN OPEN CLINICAL  EVALUTION ON SAGANAVATHAM (CERVICAL 
SPONDYLOSIS) WITH THE  SIDDHA TRIAL DRUG  “POORANATHI 
CHOORANAM”  (INTERNAL),   “VALI KUTHALUKU ULLI ENNAI”  
(EXTERNAL) AND “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY). 
1. SERIAL NO OF THE CASE: …………………   
2. OP / IP NO: ......................................   
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................   
A) BLOOD INVESTIGATIONS:                        
BLOOD INVESTIGATIONS NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
Hb ( gms/dL) M:12-15 
F:11.5-14 
  
T.RBC (millions cells / Cu.mm) M:4.0-5.5 
F:3.5-4.5 
  
ESR (mm) ½ hr. M:6-12 
F:7-18 
  
1 
hrs. 
  
 
     T.WBC (Cells / Cu.mm) 
 
4000-11000 
  
     
 
Differential 
Count (%) 
        Polymorphs    40-75  
Lymphocytes      20-40   
        Monocytes       2-10   
        Eosinophil        1-6   
        Basophils         0-1   
BLOOD INVESTIGATIONS NORMAL 
VALUES 
BEFORE 
TREATMENT 
AFTER 
TREATMENT 
 
Blood glucose (mg/dl) 
Fasting 70-110   
PP 80-140   
Random 80-160   
Serum calcium mg/dl   8.5-10.2   
Renal Function 
Test(mg/dl) 
 
Blood urea 
Serum creatinine 
  16-50   
  0.6-1.2   
Liver function 
test(mg/dl) 
Total bilirubin   0.2-1.2   
 Direct bilirubin   0.1-1.2   
.Indirect bilirubin   0.2-0.7   
 
SGOT   0-40   
 
SGPT   0-35   
 
Alkaline phosphatase  80-290   
 
B) URINE INVESTIGATIONS: 
URINE 
INVESTIGATIONS 
BEFORE TREATMENT AFTER TREATMENT 
Albumin   
Sugar   
Deposits   
 
Date:          
Station:                            Signature of the Guide: 
         
                                                                                          Signature of the Investigator:   
                           GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600106 
          POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM    
AN OPEN CLINICAL EVALUTION ON SAGANAVATHAM (CERVICAL 
SPONDYLOSIS) WITH THE SIDDHA TRIAL DRUG “POORANATHI 
CHOORANAM” (INTERNAL), “ VALI  KUTHALUKU ULLI ENNAI”  
(EXTERNAL) AND “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY). 
                                      FORM V: INFORMED CONSENT FORM 
          “I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any question I have asked has been 
answered to my satisfaction.  
            I   consent voluntarily to participate as a participant in this study and 
understand that I have the   right to withdraw from the study at any time without in 
any way it affecting my further medical care”. 
"I have received a copy of the information sheet/consent form". 
Date:                                                                                              
Signature of the participant:                                                                                                                                                                     
In case of illiterate participant: 
      “I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.”                                                   
Date: 
 
Signature of a witness:                                    Left thumb Impression of the Participant     
(Selected by the participant bearing no connection with the survey team) 
Date:       Signature of the participant: 
Station:       Signature of the Investigator:                                                              
   
  Signature of the Guide:    
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                 GOVERNMENT SIDDHA MEDICAL COLLEGE,  
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                                                         CHENNAI  106 
      POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN  CLINICAL  EVALUTION ON SAGANAVATHAM (CERVICAL 
SPONDYLOSIS) WITH THE  SIDDHA TRIAL DRUG  “POORANATHI 
CHOORANAM”  (INTERNAL),   “VALI KUTHALUKU ULLI ENNAI”  
(EXTERNAL) AND “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY). 
                             FORM VI - WITHDRAWAL FORM 
SI NO  :                 
OP NO :                                               
NAME : 
AGE / GENDER:                
DATE OF TRIAL COMMENCEMENT: 
DATE OF WITHDRAWAL FROM TRIAL: 
REASONS FOR WITHDRAWAL: 
• Long absence at reporting :                                 Yes/ No 
• Irregular treatment:                                            Yes/ No 
• Shift of locality :                                                  Yes/No 
• Increase in severity of symptoms:                      Yes/No 
• Development of severe adverse drug reactions:    Yes/No 
 
Date:          
Station:       
Signature of the Guide:                                                            
Signature of Investigator:   
                                 GOVERNMENT SIDDHA MEDICAL COLLEGE 
         ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
                                                        CHENNAI – 600 106 
        POST- GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN  CLINICAL  EVALUTION ON SAGANAVATHAM (CERVICAL 
SPONDYLOSIS) WITH THE  SIDDHA TRIAL DRUG  “POORANATHI 
CHOORANAM”  (INTERNAL),   “VALI KUTHALUKU ULLI ENNAI”  
(EXTERNAL) AND “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY) 
FORM VII – PATIENT INFORMATION SHEET 
Name of  Investigator :   Dr.R.KALAIVANI 
Name of the college     :   Govt. Siddha Medical College 
                                          Arumbakkam 
                                          Chennai-106. 
 
INFORMATION SHEET FOR PATIENTS PARTICIPATING IN THE OPEN 
CLINICAL TRIAL. 
       R.KALAIVANI  studying M.D (Siddha) at Govt.Siddha Medical College, 
Chennai,  is doing a clinical trial on „„SAGANA VATHAM” (CERVICAL 
SPONDYLOSIS). It is becoming a most common disease, occurring throughout the 
world. In this regard, I am in need to ask you few questions. I will maintain 
confidentiality of your comments and data obtained. There will be no risk of 
disclosing your identity and no physical, psychological or professional risk is 
involved by taking part in this study. Taking part in this study is voluntary. No 
compensation will be paid to you for taking part in this study. 
           You can choose not to take part. You can choose not to answer a specific 
question. There is no specific benefit for you if you take part in the study. However, 
taking part in the study may be of benefit to the community, as it may help us to 
understand the problem of defaulters and potential solutions. 
             If you agree to be a participant in this study, you will be included in the study 
primarily by signing the consent form and then you will be given the internal 
medicine “POORANATHI CHOORANAM” 1gm with honey twice a day for 48 
days, external medicine vali kuthaluku ulli ennai and otradam for external therapy. 
                The information I am collecting in this study will remain between you and 
the Co- investigator (myself). I will ask you few questions through a questionnaire. I 
will not write your name on this form. I will use a code instead. 
              
The questionnaire will take approximately 20 minutes of your time. 
            
  If you wish to find out more about this study before taking part, you can ask 
me all the questions you want or contact R.KALAIVANI, PG Scholar cum Co- 
investigator of this study, attached to Govt. Siddha Medical College, Chennai-106. 
You can also contact the Member-secretary of Ethics committee, Govt. Siddha 
Medical College, Chennai. 
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GOVERNMENT SIDDHA MEDICAL COLLEGE,  
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE,                                                 
CHENNAI 106 
 POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL EVALUTION ON SAGANAVATHAM (CERVICAL 
SPONDYLOSIS) WITH THE SIDDHA TRIAL DRUG “POORANATHI 
CHOORANAM” (INTERNAL),   “ VALI KUTHALUKU ULLI ENNAI”  
(EXTERNAL) AND “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY). 
                                                         FORM VIII 
                                             DIETARY ADVICE FORM 
             :  
      :       ,         ,                        
     . 
      :      ,           ,         ,           , 
       ,       ,                       . 
      :     ,    ,    ,      ,    ,      ,      , 
    ,       ,     ,                      . 
        :      ,   ,        ,       ,           , 
  ,                         . 
      :          ,   ,                      
     . 
             : 
           
           
          
      
        
          
GOVERNMENT SIDDHA MEDICAL COLLEGE 
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE 
CHENNAI – 600 106 
     POST -  GRADUATE- DEPARTMENT OF SIRAPPU MARUTHUVAM 
 
AN OPEN CLINICAL EVALUTION ON SAGANAVATHAM (CERVICAL 
SPONDYLOSIS) WITH THE SIDDHA TRIAL DRUG “POORANATHI 
CHOORANAM” (INTERNAL), “VALI KUTHALUKU ULLI ENNAI” 
(EXTERNAL) AND “VEPPAM PINNAKKU OTTRADAM” (EXTERNAL 
THERAPY). 
                               FORM IX   - ADVERSE REACTION FORM  
SERIAL NO:                                                                                                           
OP NO:  
NAME:                                                            
AGE:                                          
GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF OCCURRENCE OF THE ADVERSE REACTION:    
TIME: 
DESCRIPTION OF ADVERSEREACTION: 
 
Date:                    Signature of the Guide:                                                                                                                                
Station:  
 
Signature of the Investigator: 
              
 
